

MINUTES
Monthly Meeting
MEDICAL LICENSURE COMMISSION OF ALABAMA
Meeting Location: 848 Washington Avenue
Montgomery, Alabama 36104

July 27, 2023

MEMBERS PRESENT IN PERSON

Craig H. Christopher, M.D., Chairman
Jorge Alsip, M.D., Vice-Chairman
Kenneth W. Aldridge, M.D.
Howard J. Falgout, M.D.
Paul M. Nagrodzki, M.D.

MLC STAFF

Aaron Dettling, General Counsel, MLC
Rebecca Robbins, Operations Director (Recording)
Nicole Hardy, Administrative Assistant (Recording)
Heather Lindemann, Licensure Assistant

BME STAFF

Buddy Chavez, Investigator
Rebecca Daniels, Investigator
Randy Dixon, Investigator
Amy Dorminey, Operations Director
Greg Hardy, Investigator
Alicia Harrison, Associate General Counsel
Chris Hart, Technology
Effie Hawthorne, Associate General Counsel
Wilson Hunter, General Counsel
Roland Johnson, Physician Monitoring
Tiffany Seamon, Director of Credentialing

MEMBERS NOT PRESENT

L. Daniel Morris, Esq.
Pamela Varner, M.D.

OTHERS PRESENT

Gregg Everett, Esq.

Call to Order: 9:00 a.m.

Prior notice having been given in accordance with the Alabama Open Meetings Act, and with a quorum of five members present, Commission Chairman, Craig H. Christopher, M.D. convened the monthly meeting of the Alabama Medical Licensure Commission.

OLD BUSINESS

Minutes June 28, 2023

Commissioner Alsip made a motion that the Minutes of June 28, 2023, be approved. A second was made by Commissioner Nagrodzki. The motion was approved by unanimous vote.

NEW BUSINESS

Full License Applicants

<u>Name</u>	<u>Medical School</u>	<u>Endorsement</u>
1. Nima Mohamoud Abdi	Dubai Medical College for Girls	USMLE/MI
2. Munazzah Abdullah	Aureus University School of Medicine	USMLE
3. Kevin Arthur Ache	Nova Southeastern University College of Medicine	COMLEX/TN
4. Olufunke M Adebayo	American University of Antigua	USMLE/OH
5. Chante K Aksut	Columbia University College of Physicians & Surgeons	USMLE/CO
6. Ahmad Al Hamda	University of Damascus	USMLE/WI
7. Dyan Cristyn Alvarez	Fatima Jinnah Medical University	USMLE
8. Mark Karam Azmy	St. Georges University of London	USMLE
9. Kerri Bally	University of the West Indies, Trinidad	USMLE
10. Sahar Baloch Baloch	Bahria University Medical & Dental College	USMLE
11. Jazzmine C Basham	Edward Via Virginia College of Osteopathic Medicine	COMLEX/OK
12. Silvia Gesheva Baxter	Howard University College of Medicine	USMLE/TX
13. Kulsajan Singh Bhatia	Government Medical College Chandigarh	USMLE
14. Udit Bhavsar	University of Utah School of Medicine	USMLE
15. Parameshwara R Bolla	Osmania Medical College	USMLE
16. Carrie Elana Brackett	Edward Via College of Osteopathic Medicine, Carolinas Campus	COMLEX
17. Pedro R Jesus Cabrera	Francisco Marroquin University	USMLE
18. Luis G Chaves Villamil	National University of Colombia	USMLE/FL
19. Victoria L Chisholm	Lake Erie College of Osteopathic Medicine	COMLEX
20. Joseph S Coppiano	Augusta University	USMLE/GA
21. Brittain A Cross	Kansas City College of Medicine & Surgery	COMLEX/MS
22. Michele Groark Curtis	Texas Tech University Health Sciences Center School of Medicine	FLEX/TX
23. Tyler M Davidson	Edward Via Virginia College of Osteopathic Medicine	COMLEX/GA
24. Peter M DeLeeuw	University of North Texas Health Science Center	COMLEX



<u>Name</u>	<u>Medical School</u>	<u>Endorsement</u>
25. Byron Nice Detweiler	Oklahoma State University College of Osteopathic Medicine Tulsa	COMLEX/OK
26. Daniel Obadare Fijabi	Ladoke Akintola Univ of Technology College of Health Sciences	USMLE
27. Sara Elizabeth Frese	University of Alabama School of Medicine Birmingham	USMLE
28. Glenn Goodwin	Touro U College of Osteopathic Medicine	COMLEX/FL
29. Tyler Mark Hartman	Indiana University School of Medicine Indianapolis	USMLE/MN
30. Juliana Sophia Heimur	Rowan University School of Osteopathic Medicine	COMLEX
31. Rylan Holmberg	Nova Southeastern University College of Medicine	COMLEX
32. Janison Waide Hunter	University of Alabama School of Medicine Birmingham	USMLE
33. Ayesha Ikram	University of the Punjab, King Edward Medical College	USMLE/IL
34. Joanne Jacob	Baylor College of Medicine	USMLE
35. Chandra M Jennings	Edward Via College of Osteopathic Medicine, Carolinas Campus	COMLEX/CO
36. Joel Scott Johnson II	Alabama College of Osteopathic Medicine	COMLEX
37. Olufadejimi A Kareem	Windsor University	USMLE
38. Samina Sayeeda Karim	University of Alabama School of Medicine Birmingham	USMLE/FL
39. Kayla B Starling Kebbel	University of Alabama School of Medicine Birmingham	USMLE/TX
40. Jan Ole Kernnade	Baylor College of Medicine	USMLE/TX
41. Christian Y Kitamura	Univ of California Los Angeles, David Geffen School of Medicine	USMLE/HI
42. Lauren Nicole Kois	University of Alabama School of Medicine Birmingham	USMLE
43. Dhivya Kuzhandai Velu	Kilpauk Medical College, University of Chennai	USMLE
44. Peter Lambert	St Georges University of London	USMLE/OK
45. Justin Walton Lewis	University of Alabama School of Medicine Birmingham	USMLE
46. Anna Leigh Lovett	University of Mississippi School of Medicine	USMLE/VA
47. Seth Michael Martin	University of Virginia School of Medicine	USMLE/VA
48. Rachel E Mathers	University of Texas Medical School at Galveston	USMLE/TX
49. Anna G McDonald	Duke University School of Medicine	USMLE/MA
50. Asia Dionne McIntosh	Trinity School of Medicine	USMLE/FL
51. Chelsey A McKinnon	University of Central Florida College of Medicine	USMLE/NE
52. Juwairiah Mohammad	Central Michigan University College of Medicine	USMLE
53. Katrina Marie Monday	Wayne State University School of Medicine	USMLE/WI
54. Mary Margaret Moses	Augusta University	USMLE
55. Richard John Mosu	American University of the Caribbean	USMLE
56. Sara Moussa	University of Toledo College of Medicine	USMLE/MI
57. Karen Melissa Moyer	Rowan University School of Osteopathic Medicine	COMLEX/SC
58. Samina Nur	Rawalpindi Medical College, University of the Punjab	USMLE/CT
59. Brian Douglas Overman	Edward Via College of Osteopathic Medicine Auburn campus	COMLEX
60. Jonathan E Pangia	Touro University College of Osteopathic Medicine	COMLEX/NY
61. Archit S Patel	Edward Via College of Osteopathic Medicine Auburn campus	COMLEX
62. Rena Chiman Patel	Stanford University School of Medicine	USMLE/CA
63. Vincent Picascio	University of South Florida College of Medicine	USMLE/FL
64. William R Poore	University of Alabama School of Medicine Birmingham	USMLE
65. Lori Anne Proe	Kansas City University of Medicine & Biosciences	COMLEX/MO
66. Aravind Reddy	University of Toledo College of Medicine	USMLE/NY

<u>Name</u>	<u>Medical School</u>	<u>Endorsement</u>
67. Kiehyun Daniel Riew	Case Western Reserve University School of Medicine	FLEX/OH
68. Brent Christopher Ruiz	Louisiana State University Medical Center in Shreveport	USMLE
69. Jacqueline J Russo	University of Miami Miller School of Medicine	USMLE/FL
70. Morghan J Sahawneh	East Tennessee State Uni, James H Quillen College of Medicine	USMLE
71. Matthew J Sanders	Louisiana State University Medical Center in Shreveport	USMLE/IL
72. Lucas F M Sheridan	Alabama College of Osteopathic Medicine	COMLEX/GA
73. Sufana Shikdar	Ibrahim Pasha University	USMLE/OK
74. Monson Shuh	The University of Tennessee Graduate School of Medicine	NBME/USMLE/TN
75. Ashhad Shoaib Siddiqui	Windsor University	USMLE/FL
76. Fady Nabil Sidhom	American University of the Caribbean	USMLE/DC
77. Cory Daniel Smith	University of Alabama School of Medicine Birmingham	USMLE/SC
78. Brendan Ray Squier	UAB / University of Louisville School of Medicine	USMLE
79. Piotr Starakiewicz	Wayne State University School of Medicine	USMLE/NY
80. Steven Michael Stein	Ross University	USMLE/FL
81. Chelsey D Stewart	Edward Via College of Osteopathic Medicine Auburn campus	COMLEX
82. John Newton Stoffer	University of Cincinnati College of Medicine	USMLE
83. Lily Ly Truong	Louisiana State University School of Medicine New Orleans	USMLE/LA
84. Rachna Valvani	Netaji Subhash Chandra Bose Medical College	USMLE/CT
85. Avantika Varma	American University of Antigua	USMLE/GA
86. Sebastian Hugo Verne	University of Miami Miller School of Medicine	USMLE/FL
87. James Brevard Vogler	University of South Florida College of Medicine	USMLE/FL
88. Ryan Wing-Chung Wan	Michigan State University College of Osteopathic Medicine	COMLEX/MD
89. Samantha S Ware	Louisiana State University Medical Center in Shreveport	USMLE
90. Yung Shu Wong	University of Oklahoma Health Science Center	USMLE
91. John Robert Worley	University of Missouri Kansas City School of Medicine	USMLE/MO
92. William Zachary Wright	University of Virginia School of Medicine	USMLE
93. Martin Curtis Yee	University of Texas Medical School at San Antonio	USMLE/CA
94. Rebecca Adair Young	University of South Alabama College of Medicine	USMLE
95. Michelle Denise Zook	Georgetown University School of Medicine	USMLE/PA
96. Lisa Michelle Bianco	Alabama College of Osteopathic Medicine	COMLEX
97. Denise Marie Josey	Howard University College of Medicine	USMLE/NY
98. *Brianna Rene' Best	Edward Via C of Osteo Med, Carolinas Camp	COMLEX/FL
99. *Ethan Win Thein Lin	Ross University	USMLE/CA
100.*Thomas W Middleton	American University of the Caribbean	USMLE
101.*Hatem A Mourad	St. Christopher Iba Mar Diop College of Med	USMLE/FL
102.*Parin Pratik Nanavati	North Carolina Medical College	USMLE
103.*Mark Carrasco	St. Georges University of London	USMLE/CT
104.*Jeramie Rosales Rodriguez	Universidad Iberoamericana School of Med	USMLE/KY
105. Brian Joel Cooper	Philadelphia College of Osteopathic Medicine	COMLEX/TX

**Approved pending acceptance and payment of NDC issued by BME.*



A motion was made by Commissioner Aldridge with a second by Commissioner Falgout to approve applicant numbers one through one hundred and five (1-105) for full licensure. The motion was approved by unanimous vote.

Limited License Applicants

<u>Name</u>	<u>Medical School</u>	<u>Endorsement</u>	<u>Location</u>	<u>License</u>
1. Alesha C Amerson	UAB	LL/AL	UAB Tuscaloosa FM	R
2. Celia A Asinor	St. George's Univ School of Med, Grenada	LL/AL	UAB Tuscaloosa FM	R
3. Noor Buttar	Edward Via C of Osteo Med Carolina Camp	LL/AL	USA Health Pediatrics	R
4. Yu-Yun C Chen	New York College of Osteopathic Medicine	LL/AL	Crestwood Graduate IM	R
5. Danielle Devore	Lincoln Mem U Debusk C of Osteo Med	LL/AL	Crestwood Graduate IM	R
6. Fnu Ekta	Chandka Medical College Univ of Sind	LL/AL	USA IM	R
7. Bridget L Forbes	Edward Via C of Osteo Med Auburn Camp	LL/AL	South Baldwin FM	R
8. Kiah J Gledhill	University of Kentucky College of Medicine	LL/AL	USA Surgery	R
9. Katy Ellen Gregory	Univ of Mississippi School of Medicine	LL/AL	South Baldwin FM	R
10. Anna B Gregory	UAB	LL/AL	Gadsden Regional FM	R
11. Kristen Harvey	Univ of Mississippi School of Medicine	LL/AL	Cahaba FM	R
12. Kenzie B Hendrix	William Carey U College of Osteo Med	LL/AL	South Baldwin FM	R
13. Daniel Isaza Pierotti	Universidad Del Valle, Cali	LL/AL	USA Neurology	R
14. Garrett S Jackson	Texas Tech Univ School of Medicine	LL/AL	Cahaba FM	R
15. Marcus H Lackey	Florida State Univ College of Medicine	LL/AL	USA Psychiatry	R
16. Matthew R Land	Georgia School of Medicine	LL/AL	Cahaba FM	R
17. Madison B Lee	UAB	LL/AL	USA IM	R
18. Cody Ryan Miller	Alabama College of Osteopathic Medicine	LL/AL	USA Psychiatry	R
19. Razan Mohty	Lebanese University	LL/AL	UAB Hematology/Oncology	SP
20. David Alex Monaco	UAB	LL/AL	USA Emergency Medicine	R
21. Chimerezeze Ndubuke	Windsor University	LL/AL	USA Pediatrics	R
22. Ashley Nguyen	USA College of Medicine	LL/AL	USA Neurology	R
23. Matthew Allen Norris	Alabama College of Osteopathic Medicine	LL/AL	USA OB/GYN	R
24. Kevin James Parham	Virginia Commonwealth School of Med	LL/AL	USA Urology	R
25. Daniel Raza	Tulane University School of Medicine	LL/AL	USA FM	R
26. Saeed Razaq	Kabir Medical College	LL/AL	UAB Nephrology Dept	F
27. Adriana Reyes Moon	UAB	LL/AL	USA IM	R
28. Stephen Richardson	Edward Via C of Osteo Med Auburn Camp	LL/AL	USA Psychiatry	R
29. Melissa C Saganich	Edward Via C of Osteo Med Carolina Camp	LL/AL	Cahaba FM	R
30. Rajkumar Selvanayagam	Tamil Nadu Dr. M.G.R. Medical University	LL/AL	UAB Orthopedic Surgery	F
31. Juhi Shah	Univ of North Texas Health Science Center	LL/AL	USA OB/GYN	R
32. Adnan Hussain Shahid	Mahatma Gandhi Mem Med C, Indore U	LL/AL	USA Skull /Neuro Oncology	F
33. Olumayowa B Sholola	Windsor University	LL/AL	USA Pediatrics	R
34. Richard Joseph Sliva	University of Kansas School of Medicine	LL/AL	USA Neurology	R
35. Sawyer John Stevens	Univ of S Dakota School of Med Vermillion	LL/AL	South Baldwin FM	R



<u>Name</u>	<u>Medical School</u>	<u>Endorsement</u>	<u>Location</u>	<u>License</u>
36. Larry Collins Stutts II	Alabama College of Osteopathic Medicine	LL/AL	USA FM	R
37. Khawla Suhaila	UAB	LL/AL	Cahaba FM	R
38. Juan A Teron-Cosme	U of Med and Health Sciences, St. Kitts	LL/AL	USA IM	R
39. Elizabeth May Trushaw	UAB	LL/AL	Cahaba FM	R
40. Dimitri Jorge Villanueva	American University of The Caribbean	LL/AL	USA FM	R
41. Vibhu K Viswanathan	Madras Medical College	LL/AL	UAB Orthopedic Surgery	F
42. Ann Marie Walker	Univ of Medicine and Health Sciences	LL/AL	USA Emergency Medicine	R
43. James Bryant Wisdom Jr.	Edward Via C of Osteo Med Auburn Camp	LL/AL	USA FM	R
44. Sindhu Yarrabelli	Chalmeda Anand Rao Institute of Med Sci	LL/AL	Southeast Hlth Trans Year	R
45. Katherine Sweeney	Touro U College of Osteo Med	LL/AL	UA Tuscaloosa FM Res Pro	R

A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to approve applicant numbers one through forty-five (1-45) for limited licensure. The motion was approved by unanimous vote.

Provisional License Applicants

<u>Name</u>	<u>Medical School</u>	<u>Endorsement</u>
1. Moninder Kaur Dhillon	Medical University of the Americas (Nevis)	USMLE
2. Michael Zoueter	American University of Antigua	USMLE

A motion was made by Commissioner Aldridge with a second by Commissioner Alsip to approve applicant numbers one and two (1 and 2) for provisional licensure. The motion was approved by unanimous vote.

Retired Senior Volunteer License Applicants

<u>Name</u>	<u>Location</u>
1. Stephen Lee Beaty	Cahaba Medical Care Foundation, Birmingham, AL

A motion was made by Commissioner Alsip with a second by Commissioner Falgout to approve applicant number one (1) for retired senior volunteer licensure. The motion was approved by unanimous vote.



IMLCC Report

The Commission received as information a report of the licenses that were issued via the Interstate Medical Licensure Compact from June 1, 2023, through June 30, 2023. A copy of this report is attached as Exhibit "A".

APPLICANTS FOR REVIEW

Omar Alkhatib, M.D.

A motion was made by Commissioner Aldridge with a second by Commissioner Falgout to approve Dr. Alkhatib's application for full licensure. The motion was approved by unanimous vote.

Shawn Barker, M.D.

A motion was made by Commissioner Alsip with a second by Commissioner Falgout to approve Dr. Barker's application for full licensure. The motion was approved by unanimous vote.

Harijus Birk, M.D.

A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to defer any action on Dr. Birk's application at this time. The motion was approved by unanimous vote.

Arthur Boyd, III, M.D.

A motion was made by Commissioner Nagrodzki with a second by Commissioner Aldridge to approve Dr. Boyd's application for full licensure. The motion was approved by unanimous vote.

Richard Hayward, M.D.

A motion was made by Commissioner Alsip with a second by Commissioner Falgout to approve Dr. Hayward's application for full licensure. The motion was approved by unanimous vote.

Wesley S. Hoskyns, D.O.

A motion was made by Commissioner Alsip with a second by Commissioner Aldridge to approve Dr. Hoskyns' application for full licensure. The motion was approved by unanimous vote.

A handwritten signature in black ink, appearing to be 'C. H. E.' or similar, located at the bottom left of the page.

Jacob Mathai, M.D.

A motion was made by Commissioner Alsip with a second by Commissioner Aldridge to approve Dr. Mathai's application for licensure with the same restrictions that exist upon Dr. Mathai's Certificate of Qualification pursuant to his Voluntary Restriction with the Alabama State Board of Medical Examiners. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "B".

REPORTS

Physician Monitoring Report

The Commission received as information the physician monitoring report dated July 20, 2023. A copy of the report is attached as Exhibit "C".

DISCUSSION ITEMS

Cessation of Deferral Option for Licenses

A motion was made by Commissioner Alsip with a second by Commissioner Aldridge to cease the option currently offered to applicants to defer issuance of medical licenses and reinstated licenses to January 1. The motion was approved by unanimous vote.

BME Rule for Publication: Physician Workforce Act of 2023 – Rule Amendments

The Commission received as information the BME Rule for Publication: Physician Workforce Act of 2023 Rule Amendments. A copy of the rule is attached as Exhibit "D".

BME Rule for Publication: Administrative Rule 540-X-4-.07 Emergency Prescription Refill

The Commission received as information the BME Rule for Publication: Administrative Rule 540-X-4-.07 Emergency Prescription Refill. A copy of the rule is attached as Exhibit "E".

BME Rule for Publication: Joint Committee on Pharmacy Collaborative Practice – Rule Amendments

The Commission received as information the BME Rule for Publication: Joint Committee on Pharmacy Collaborative Practice – Rule Amendments. A copy of the rule is attached as Exhibit "F".



Melissa A. West, M.D.

The Commission received as information an update on Dr. West, by Aaron Dettling, General Counsel.

Lauren Duensing, M.D.

A motion was made by Commissioner Alsip with a second by Commissioner Aldridge to enter an order setting a hearing for January 24, 2024. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "G".

Namitha Thotli, M.D.

A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to provisionally approve Dr. Thotli's application for limited licensure. The motion was approved by unanimous vote.

REQUESTS

James Steven St. Louis, D.O.

The Commission considered Dr. St. Louis' request to withdraw his application for reinstatement. A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to enter an order to dismiss the Administrative Complaint filed by the Alabama State Board of Medical Examiners without prejudice. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "H".

Ramesh Babu Peramsetty, M.D.

The Commission considered Dr. Peramsetty's request to terminate probation one year early. A motion was made by Commissioner Alsip with a second by Commissioner Aldridge to set a hearing for February 28, 2024. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "I".

Janie Teschner, M.D.

The Commission considered the proposed practice plan submitted by Dr. Teschner. A motion was made by Commissioner Alsip with a second by Commissioner Aldridge to approve the



proposed practice plan with stipulations. A copy of the Commission's order is attached hereto as Exhibit "J".

ADMINISTRATIVE FILINGS

William H. Barton, III, M.D.

The Commission received a Joint Settlement Agreement and Consent Order between Dr. Barton and the Alabama State Board of Medical Examiners. A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to accept the Joint Settlement Agreement and to enter a Consent Decree incorporating its terms. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "K".

Christopher P. Gay, D.O.

A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to approve the Bill of Costs filed by the Alabama State Board of Medical Examiners. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "L".

Aaron A.H. Ramirez, M.D.

The Commission received a Motion to Continue Hearing regarding the Administrative Complaint filed by the Alabama State Board of Medical Examiners. A motion was made by Commissioner Nagrodzki with a second by Commissioner Falgout to enter an order resetting the hearing for January 24, 2024. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "M".

Gary Royce Wisner, M.D.

The Commission received as information Dr. Wisner's answer to the Administrative Complaint filed by the Alabama State Board of Medical Examiners.

Mishi Bhushan, M.D.

The Commission received as information the order Terminating the Voluntary Restrictions on Dr. Bhushan's medical license filed by the Alabama State Board of Medical Examiners.



Barry Gene Collins, M.D.

The Commission received an Administrative Complaint filed by the Alabama State Board of Medical Examiners. A motion was made by Commissioner Nagrodzki with a second by Commissioner Falgout to enter an order assigning the matter to a three-member hearing panel and setting a hearing for September 12, 2023. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "N".

Eric Ray Beck, M.D.

The Commission received an Administrative Complaint filed by the Alabama State Board of Medical Examiners. A motion was made by Commissioner Alsip with a second by Commissioner Nagrodzki to enter an order setting a hearing for December 20, 2023. The motion was approved by unanimous vote. A copy of the Commission's order is attached hereto as Exhibit "O".

Meeting adjourned at 11:29 a.m.

PUBLIC MEETING NOTICE: The next meeting of the Alabama Medical Licensure Commission was announced for Wednesday, August 23, 2023, beginning at 9:00 a.m.


CRAIG H. CHRISTOPHER, M.D., Chairman
Alabama Medical Licensure Commission


Rebecca Robbins, Director of Operations
Recording Secretary
Alabama Medical Licensure Commission

08/13/2023
Date Signed



EXHIBIT A

IMLCC Licenses Issued June 1, 2023 - June 30, 2023 (104)

Name	License Type	License Number	Status	Issue Date	Expiration Date	State of Principal Licensure
Sophia Yen	MD	46691	Active	6/12/2023	12/31/2023	Arizona
Andrew David Thompson	MD	46692	Active	6/12/2023	12/31/2023	Arizona
Marvin Hill	MD	46707	Active	6/20/2023	12/31/2023	Arizona
Claudia H Martin	MD	46678	Active	6/8/2023	12/31/2023	Colorado
Jeffrey Randall Boris	MD	46680	Active	6/8/2023	12/31/2023	Colorado
Raj Kandavanam	MD	46690	Active	6/12/2023	12/31/2023	Colorado
Michael Patrick McGurren	MD	46700	Active	6/14/2023	12/31/2023	Colorado
Amelia A Smith-Dixon	MD	46702	Active	6/15/2023	12/31/2023	Colorado
Lisa Meredith Hile	MD	46731	Active	6/23/2023	12/31/2023	Colorado
Vinod Thukral	MD	46807	Active	6/30/2023	12/31/2023	Colorado
Thomas Liu	DO	3313	Active	6/6/2023	12/31/2023	Georgia
Eddie Clifford Beal	MD	46681	Active	6/8/2023	12/31/2023	Georgia
Walkiria Alexander Smith	MD	46682	Active	6/8/2023	12/31/2023	Georgia
Thomas Martin Hagopian	MD	46693	Active	6/13/2023	12/31/2023	Georgia
Constantin Nzoukio Chikando	MD	46694	Active	6/13/2023	12/31/2023	Georgia
Norman Arthur Hetzler	MD	46710	Active	6/20/2023	12/31/2023	Georgia
Jacqueline Michele OKane	DO	3324	Active	6/27/2023	12/31/2023	Georgia
Rania Hafeth Mahmoud Saleh	MD	46659	Active	6/2/2023	12/31/2023	Illinois
Jennifer Louise Vakharia	MD	46699	Active	6/14/2023	12/31/2023	Illinois
Karissa Ann Ellis	DO	3317	Active	6/12/2023	12/31/2023	Indiana
Ralph Warren Richardson	MD	46679	Active	6/8/2023	12/31/2023	Kansas
Paula Dix Johnson	MD	46686	Active	6/9/2023	12/31/2023	Kentucky
Richard James Tramel	MD	46654	Active	6/2/2023	12/31/2023	Louisiana
Charise Shively Fashho	MD	46672	Active	6/6/2023	12/31/2023	Louisiana
Georges Elias El Khoury Antoun	MD	46695	Active	6/13/2023	12/31/2023	Louisiana
Garrick James Slate	MD	46661	Active	6/6/2023	12/31/2023	Maine
Tatiana Oana Chesnut	MD	46708	Active	6/20/2023	12/31/2023	Maine
Joel Radhames Nunez Gonzalez	MD	46676	Active	6/7/2023	12/31/2023	Maryland

Christine Mary Ryan	DO	3311	Active	6/1/2023	12/31/2023	Michigan
Adriana Serje Tanner	MD	46721	Active	6/21/2023	12/31/2023	Michigan
Rabia Asghar Cacco	MD	46725	Active	6/22/2023	12/31/2023	Michigan
Gjon Dushaj	MD	46732	Active	6/23/2023	12/31/2023	Michigan
Christina Elaine Dewey	MD	46734	Active	6/26/2023	12/31/2023	Minnesota
Kristi Kay Trimm	DO	3323	Active	6/26/2023	12/31/2023	Mississippi
Ronald David Dean	DO	3322	Active	6/26/2023	12/31/2023	Montana
Leslie Alison Greenberg	MD	46697	Active	6/13/2023	12/31/2023	Nevada
Choua Thao	MD	46814	Active	6/30/2023	12/31/2023	Nevada
Sunil Rathore	MD	46668	Active	6/6/2023	12/31/2023	Ohio
Sandeep Palakodeti	MD	46683	Active	6/8/2023	12/31/2023	Ohio
Gerald Noriyuki Maesaka	MD	46685	Active	6/9/2023	12/31/2023	Ohio
Travis John Ptacek	MD	46653	Active	6/2/2023	12/31/2023	South Dakota
Cleopatra Nsofwa Thurman	DO	3315	Active	6/9/2023	12/31/2023	Tennessee
Curtis Garrison	DO	3316	Active	6/9/2023	12/31/2023	Tennessee
Howard Mather Bennett	MD	46720	Active	6/21/2023	12/31/2023	Tennessee
Stephen Sabourin	MD	46737	Active	6/27/2023	12/31/2023	Tennessee
Muhammad F Asghar	MD	46647	Active	6/1/2023	12/31/2023	Texas
Aileen Betty Chen	MD	46648	Active	6/1/2023	12/31/2023	Texas
Gary Brandon Gunn	MD	46649	Active	6/1/2023	12/31/2023	Texas
Justin Wong	MD	46650	Active	6/1/2023	12/31/2023	Texas
Peiman Habibollahi	MD	46651	Active	6/2/2023	12/31/2023	Texas
Lauren Laver Mayo	MD	46652	Active	6/2/2023	12/31/2023	Texas
Ayesha Zia Zuberi	MD	46656	Active	6/2/2023	12/31/2023	Texas
Amy Catherine Moreno	MD	46657	Active	6/2/2023	12/31/2023	Texas
Krina Kiritkumar Patel	MD	46658	Active	6/2/2023	12/31/2023	Texas
Benjamin L Rawson	DO	3312	Active	6/2/2023	12/31/2023	Texas
Thomas Michael Wheeler	MD	46660	Active	6/6/2023	12/31/2023	Texas
Ouida Lenaine Westney	MD	46662	Active	6/6/2023	12/31/2023	Texas
Ryan Patrick Goepfert	MD	46663	Active	6/6/2023	12/31/2023	Texas

John Francis Ward III	MD	46664	Active	6/6/2023	12/31/2023	Texas
Jose Antonio Karam	MD	46665	Active	6/6/2023	12/31/2023	Texas
Lisly Joel Chery	MD	46666	Active	6/6/2023	12/31/2023	Texas
Vanessa Michelle Pearson	MD	46669	Active	6/6/2023	12/31/2023	Texas
Merrick Ira Ross	MD	46674	Active	6/7/2023	12/31/2023	Texas
Merry Chen	MD	46675	Active	6/7/2023	12/31/2023	Texas
Bradley Prestidge	MD	46677	Active	6/8/2023	12/31/2023	Texas
Z Hye Lee	MD	46684	Active	6/9/2023	12/31/2023	Texas
Ashish Madhav Kamat	MD	46687	Active	6/9/2023	12/31/2023	Texas
Eduardo Raul Elizondo	MD	46688	Active	6/12/2023	12/31/2023	Texas
Jasneet Riar	MD	46689	Active	6/12/2023	12/31/2023	Texas
Kate Shaw Baron	MD	46698	Active	6/13/2023	12/31/2023	Texas
Anil K Sood	MD	46701	Active	6/14/2023	12/31/2023	Texas
Shannon Neville Westin	MD	46703	Active	6/16/2023	12/31/2023	Texas
Michael Maxwell Frumovitz	MD	46704	Active	6/16/2023	12/31/2023	Texas
Kathleen Marie Schmeler	MD	46705	Active	6/16/2023	12/31/2023	Texas
Jessica Edwards	DO	3318	Active	6/16/2023	12/31/2023	Texas
Ravin Ratan	MD	46706	Active	6/20/2023	12/31/2023	Texas
David Allan Marquis	DO	3319	Active	6/20/2023	12/31/2023	Texas
Michel Choueiri	MD	46711	Active	6/20/2023	12/31/2023	Texas
Neeta Somaiah	MD	46712	Active	6/20/2023	12/31/2023	Texas
Henry Chang	DO	3320	Active	6/20/2023	12/31/2023	Texas
Meghan Sri Karuturi	MD	46713	Active	6/20/2023	12/31/2023	Texas
Rachel Michelle Layman	MD	46714	Active	6/20/2023	12/31/2023	Texas
Jennifer Keating Litton	MD	46715	Active	6/21/2023	12/31/2023	Texas
Spencer James Frink	MD	46716	Active	6/21/2023	12/31/2023	Texas
Scott Elliott Evans	MD	46717	Active	6/21/2023	12/31/2023	Texas
Rashmi Krishna Murthy	MD	46718	Active	6/21/2023	12/31/2023	Texas
Thomas Gillispie Smith	MD	46719	Active	6/21/2023	12/31/2023	Texas
Matthew David Coffman	MD	46722	Active	6/21/2023	12/31/2023	Texas

Meroe Bergman Morse	MD	46726	Active	6/23/2023	12/31/2023	Texas
Yinghong Wang	MD	46727	Active	6/23/2023	12/31/2023	Texas
Brian Keith Bednarski	MD	46728	Active	6/23/2023	12/31/2023	Texas
Joshua David Kuban	MD	46729	Active	6/23/2023	12/31/2023	Texas
Bruce Fernando Sabath	MD	46730	Active	6/23/2023	12/31/2023	Texas
Biruh Twsefa Workeneh	MD	46733	Active	6/26/2023	12/31/2023	Texas
Dristhi Servani Ragoonanan	MD	46735	Active	6/26/2023	12/31/2023	Texas
Chitra Hosing	MD	46736	Active	6/26/2023	12/31/2023	Texas
Jessie Zexi Yu	MD	46792	Active	6/28/2023	12/31/2023	Texas
Madhuri Tirumandas	MD	46796	Active	6/29/2023	12/31/2023	Texas
Kei Cheung Ko	MD	46808	Active	6/30/2023	12/31/2023	Texas
Jared Lon Szymanski	DO	3321	Active	6/21/2023	12/31/2023	Utah
George John Melnyk	MD	46655	Active	6/2/2023	12/31/2023	Wisconsin
Joseph Y Ahn	MD	46667	Active	6/6/2023	12/31/2023	Wisconsin
Omar Saud Waqhar	DO	3314	Active	6/6/2023	12/31/2023	Wisconsin
Frank Duncan MacDonald Jr.	MD	46709	Active	6/20/2023	12/31/2023	Wisconsin

**Total licenses issued since April 2017 - 2,972*

In re:

JACOB K. MATHAI, M.D.

**BEFORE THE MEDICAL
LICENSURE COMMISSION
OF ALABAMA**

ORDER

This matter is before the Medical Licensure Commission of Alabama on the application for licensure of Jacob K. Mathai, M.D. Dr. Mathai has executed a voluntary restriction on his Certificate of Qualification, limiting his practice in Alabama to the confines to the Jackson Hospital and Clinic Family Medicine Residency Program.

The Commission grants and issues a license to practice medicine in the State of Alabama to Jacob K. Mathai, M.D., likewise restricted to the Jackson Hospital and Clinic Family Medicine Residency Program. *See* Ala. Code § 34-24-361(g) ("If the board attaches restrictions to a physician's . . . certificate of qualification, it shall notify the commission of the restrictions and the commission shall also place the restrictions on the physician's . . . license to practice medicine or osteopathy in the State of Alabama."). This restriction may be removed only by further order of the Commission.

DONE on this the 1st day of August, 2023.

**THE MEDICAL LICENSURE
COMMISSION OF ALABAMA**

By:

**E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:52:40 CDT**

**Craig H. Christopher, M.D.
its Chairman**



EXHIBIT C

STATE of ALABAMA
MEDICAL LICENSURE COMMISSION

To: Medical Licensure Commission
From: Nicole Hardy
Subject: July Physician Monitoring Report
Date: 7/20/2023

The physicians listed below are currently being monitored by the MLC.

Physician: Scott Hull Boswell, M.D.

Order Type: MLC

Due Date: Quarterly

Order Date: 12/1/2014

License Status: Active

Requirements: Therapist Report
Check PDMP

Received: Therapist Report
PDMP Compliant

Physician: Gary M. Bullock, D.O.

Order Type: MLC

Due Date: Other

Order Date: 1/26/2022

License Status: Active-Probation

Requirements: Administrative Cost (\$27,460.27)
Administrative Fine (\$20,000)
Monthly payments of \$160 for 6 months (February 2023 – July 2023)
Monthly payments of \$4,066.57 starting August 2023

Received: \$160 payment received 7/18/2023
Administrative Cost balance \$27,300.27
Administrative Fine balance \$17,312.00

Physician: Dylan E. Caggiano, D.O.
Order Type: MLC
Due Date: Quarterly
Order Date: 12/3/2021
License Status: Active
Requirements: APHP Report
Received: Report from Rob Hunt with supporting documents

Physician: Ronald Edwin Calhoun, M.D.
Order Type: BME/MLC
Due Date: Quarterly
Order Date: 3/25/2014
License Status: Active
Requirements: APHP Report
Received: Report from Rob Hunt with supporting documents

Physician: Daniel Clanton Clower, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 1/22/2015
License Status: Active
Requirements: Limited Prescribing
Worksite report from Dr. Park T. Chittom
Received: PDMP Complaint
Report from Dr. Chittom

Physician: Ran Halleluyan, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 9/28/2022
License Status: Active-Restricted
Requirements: Psychiatrist Report
Received: Report from Dr. Harold Veits

Physician: Jerry Hankins, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 9/2/2016
License Status: Active
Requirements: Limited Practice/Prescribing
Received: PDMP Compliant

Physician: Mark Koch, D.O.
Order Type: MLC
Due Date: Quarterly
Order Date: 10/25/2022
License Status: Active-Restricted
Requirements: APHP Report
CPEP Compliance Report
Received: Report from Rob Hunt with supporting documents
Compliance Email from CPEP

Physician: Barry Neal Lumpkins, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: No order in place
License Status: Active
Requirements: Check PDMP Quarterly
Received: PDMP Compliant

Physician: Edith Helga Gubler McCreadie, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 9/10/2019
License Status: Active-Probation
Requirements: Limited Prescribing
Received: PDMP Complaint

Physician: Frances Delaine Salter, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 10/4/2005
License Status: Active
Requirements: APHP Report
Received: Report from Rob Hunt with supporting documents

Physician: Hobert James Sharpton, D.O.
Order Type: MLC
Due Date: Quarterly
Order Date: No order in place
License Status: Active
Requirements: Check PDMP Quarterly
Received: PDMP Compliant

Physician: Colin G. Stafford, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 2/24/2021
License Status: Active
Requirements: APHP Report
Received: Report from Rob Hunt with supporting documents

Physician: Janie T. Bush Teschner, M.D.
Order Type: BME/MLC
Due Date: Other
Order Date: 4/19/2023
License Status: Active-Probation
Requirements: APHP Report
Practice Plan
Limited Practice (Pending practice place approval)
Therapist Report
AA/NA Meetings
CME
Received: Report from Rob Hunt with supporting documents
*Per communication with Dr. Teschner and APHP no CME courses or
polygraphs have been complete due to financial reasons.

Physician: Charles R. Thompson, M.D.
Order Type: MLC
Due Date: Quarterly
Order Date: 10/27/2021
License Status: Active
Requirements: Check PDMP Quarterly
Received: PDMP Compliant



EXHIBIT D

ALABAMA STATE BOARD OF MEDICAL EXAMINERS

WILLIAM M. PERKINS, EXECUTIVE DIRECTOR

P.O. BOX 946
MONTGOMERY, ALABAMA 36101-0946
848 WASHINGTON AVE.
MONTGOMERY, ALABAMA 36104

TELEPHONE: (334) 242-4116
E MAIL: bme@albme.gov

MEMORANDUM

To: Medical Licensure Commission
From: Mandy Ellis
Date: July 20, 2023
Re: Administrative Rules Approved for Publication

The Board of Medical Examiners, at its meeting July 20, 2023, approved the following rules to be published for public comment in the *Alabama Administrative Monthly*:

Physician Workforce Act of 2023 – Rule Amendments

- Administrative Rule 540-X-2-.03, *Definitions Generally Applicable*
- Administrative Rule 540-X-3-.03, *Post-Graduate Education Requirements*
- Administrative Rule 540-X-3-.05, *Criminal History Background Check*
- Administrative Rule 540-X-3-.07, *Additional Requirements for Examination for Certain Applicants*

In addition to providing for the practice of medicine by a bridge year graduate physician, the Physician Workforce Act of 2023:

- Defines the terms “expedited license” and “legend drug”;
- Reduces the number of postgraduate training years from three to two for applicants who graduated from a college of medicine not accredited by the Liaison Committee on Medical Education or a college of osteopathy not accredited by the Commission on Osteopathic College Accreditation;
- Eliminates the requirement of a licensure exam in the past ten years for COQ applicants; and
- Clarifies that the criminal history background check applies to certification of eligibility for an expedited license (IMLC)

The four rule amendments are proposed to comport with the portions of the new law and shall be considered in effect August 1, 2023, excluding the Bridge Year Graduate Physician Permit which requires the adoption of more extensive rules.

With an expected publication date of July 31, 2023, the public comment period ends September 4, 2023.

Attachments:

Administrative Rule 540-X-2-.03, *Definitions Generally Applicable*

Administrative Rule 540-X-3-.03, *Post-Graduate Education Requirements*

Administrative Rule 540-X-3-.05, *Criminal History Background Check*

Administrative Rule 540-X-3-.07, *Additional Requirements for Examination for Certain Applicants*

540-X-2-.03 Definitions Generally Applicable.

(1) Unless otherwise indicated from the context, the following definitions shall apply to the Rules of the Alabama Board of Medical Examiners:

(a) PHYSICIAN. Either a doctor of medicine or a doctor of osteopathy.

(b) LICENSED TO PRACTICE MEDICINE. Both the practice of medicine by a doctor of medicine or the practice of osteopathy by a doctor of osteopathy.

(c) DOCTOR. Both doctors of medicine and doctors of osteopathy.

(d) EXPEDITED LICENSE. Any license, certificate of qualification, or certification of eligibility for any license or certificate of qualification, that is intended by statute or administrative regulation to be issued in an accelerated manner.

(e) LEGEND DRUG. Any drug, medicine, chemical, or poison, bearing on the label the words, "Caution: Federal Law prohibits dispensing without a prescription" or similar words indicating that the drug, medicine, chemical, or poison may be sold or dispensed only upon the prescription of a licensed medical practitioner, except that the term legend drug shall not include any drug, substance, or compound that is listed in Schedules I through V of the Alabama Uniform Controlled Substances Act.

Author: Alabama Board of Medical Examiners

Statutory Authority: Ala. Code § 34-24-53, 34-24-53.1

History: Adopted as new rule June 6, 2002. Effective Date: September 26, 2002.

540-X-3-.03 Post-Graduate Education Requirements.

(1) Applicants for a certificate of qualification who graduated from a college of medicine accredited by the Liaison Committee on Medical Education or a college of osteopathy accredited by the Commission on Osteopathic College Accreditation shall present evidence satisfactory to the Board that the applicant has completed one (1) year of post-graduate or residency training in any of the following programs:

- (a) A program accredited by the Accreditation Council for Graduate Medical Education.
- (b) A program accredited by the American Osteopathic Association.
- (c) A program accredited by the Accreditation Committee of Royal College of Physicians and Surgeons of Canada
- (d) A program accredited by the College of Family Physicians of Canada.
- (e) Documentation submitted through the Federation Credentials Verification Service (FCVS) may be accepted to demonstrate compliance with subparagraphs (a), (b), (c), and (d) above.

(2) Applicants for a certificate of qualification who graduated from a college of medicine not accredited by the Liaison Committee on Medical Education or a college of osteopathy not accredited by the Commission on Osteopathic College Accreditation shall present evidence satisfactory to the Board that the applicant has completed ~~three~~ two (32) years of post-graduate or residency training in any of the following programs:

- (a) A program accredited by the Accreditation Council for Graduate Medical Education.
- (b) A program accredited by the Commission on Osteopathic College

Accreditation.

(c) A program accredited by the Accreditation Committee of the Royal College of Physicians and Surgeons of Canada.

(d) A program accredited by the College of Family Physicians of Canada.

(e) Documentation submitted through the Federation Credentials Verification Service (FCVS) may be accepted to demonstrate compliance with subparagraphs (a), (b), (c), and (d) above.

(3) The terms "has completed one (1) year of post-graduate or residency training" and "has completed ~~three-two~~ (32) years of post-graduate or residency training" shall mean that the applicant has successfully completed or met the program's established criteria, standards or requirements which are necessary for promotion to the next level of post-graduate training or that the applicant has successfully completed or met the program's established criteria, standards or requirements which are necessary for completion of the program.

(4) Merely accumulating twelve (12) months of post-graduate or residency training or ~~thirty-six~~ twenty-four (36~~24~~) months of post-graduate or residency training shall not be evidence satisfactory to the Board that the applicant has fulfilled the post-graduate education requirement necessary for qualifying for the issuance of a certificate of qualification for a license to practice medicine in Alabama.

Author: Alabama Board of Medical Examiners

Statutory Authority: Code of Ala. 1975, §34-24-53; Act No. 93-148.

History: Filed May 20, 1993 for publication. See also Notice of Intended Action dated May 20, 1993 repealing existing Chapter 3. Amended: July 21, 1993; effective August 25, 1993. Amended: Filed November 20, 1997; effective December 25, 1997. Amended: Filed August 23, 1999; effective August 30, 1999. Amended: Filed August 22, 2002; effective September 26, 2002. Amended: Filed March 11, 2010; effective April 15, 2010. Certified Rule Filed

December 20, 2021. Effective Date: February 13, 2022.

540-X-3-.05 Criminal History Background Check.

(1) Beginning October 1, 2008, all applicants for a certificate of qualification or certification of eligibility for any expedited license shall submit to a criminal history background check ~~to~~by the Board, ~~or any channeler approved by the Board,~~ by providing fingerprints and executing a criminal history information release using forms provided by the Board.

(a) Each applicant shall submit a complete set of fingerprints, either inked cards or electronically, properly executed by a law enforcement agency or an individual properly trained in fingerprinting techniques.

(2) Fingerprints provided by each applicant shall be submitted by the Board to the Alabama State Bureau of Investigation (SBI), which is responsible for forwarding the fingerprints to the Federal Bureau of Investigation (FBI) for a national criminal history record check.

(3) The applicant shall pay directly to the Board, or its designee, all costs associated with the background check required by this rule. ~~Costs associated with conducting a criminal history background check shall be borne by the applicant and are payable directly to the Board, or its designee.~~

(4) Information received by the Board pursuant to a criminal history background check shall be confidential and shall not be a public record, except that such information received by and relied upon by the Board in denying the issuance of a certificate of qualification for a license to practice medicine in Alabama, or relied upon in denying the issuance of, or certification of eligibility for, any expedited license may be disclosed as may be necessary to support the denial.

Author: Alabama Board of Medical Examiners

Statutory Authority: Code of Ala. 1975, §§§ 34-24-53, 34-24-70.

History: New Rule: Filed October 15, 2008; effective November 19, 2008.

Certified Rule Filed December 20, 2021. Effective Date: February 13, 2022.

540-X-3-.07 Additional Requirements for Examination for Certain Applicants.

~~(1) All applicants who have not passed the United States Medical Licensing Examination, the Comprehensive Osteopathic Medical Licensing Examination, the Licentiate of the Medical Council of Canada Examination, or the Special Purpose Examination within ten (10) years immediately preceding the date of the application shall either:~~

- ~~(a) Achieve a minimum score of 75 on the Special Purpose Examination; or~~
- ~~(b) Be certified by or achieve a passing score on a recertification examination given by one of the specialty boards approved by the American Board of Medical Specialties or one of the specialty boards approved by the American Osteopathic Association within ten (10) years immediately preceding the date of the application. This requirement may be satisfied by active participation by the applicant in a maintenance of certification program, established by one of the specialty boards approved pursuant to this subparagraph, for a period of at least one year before submission of the application.~~

(12) The SPEX shall be administered at dates and times to be established by the Examination Board of the Federation of State Medical Boards of the United States, Inc. pursuant to policies and procedures established by the Federation of State Medical Boards of the United States, Inc.

(32) SPEX Eligibility:

(a) The following individuals are eligible to take the Special Purpose Examination in Alabama:

1. Applicants who are applying for licensure in Alabama who are required to take the examination under another provision of this section.

2. Individuals required to take the examination pursuant to an order or directive of the State Board of Medical Examiners or the Medical Licensure Commission.

(b) All applicants for a certificate of qualification who are required to achieve a passing score on the SPEX shall have achieved a passing score in not more than three (3) administrations. Applicants who have not achieved a passing score within three (3) administrations shall no longer be eligible to take the SPEX.

(c) Individuals required to take the SPEX pursuant to a Board order or directive shall have achieved a passing score in not more than three (3) administrations, and those individuals who have not achieved a passing score within three (3) administrations shall no longer be eligible to take the SPEX.

(43) Endorsement applicants who are required to take the SPEX and who choose to take the SPEX through a licensing jurisdiction other than the State of Alabama must have proof of passage of the SPEX sent directly from the Federation of State Medical Boards of the United States, Inc. to the Alabama Board of Medical Examiners. Applicants may request that a certified transcript of their SPEX score be forwarded by the Federation of State Medical Boards of the United States, Inc. to the Alabama Board of Medical Examiners. An application will not be deemed complete until such proof of passage of the SPEX is received by the Alabama State Board of Medical Examiners.

(54) Documentation submitted through the Federation Credentials Verification Service (FCVS) may be accepted to demonstrate compliance with the requirements of this rule.

Author: Alabama State Board of Medical Examiners

Statutory Authority: Code of Ala. 1975, §34-24-53; Act No. 93-148. History: Filed May 20, 1993 for publication. See also Notice of Intended Action dated May 20, 1993 repealing existing Chapter 3. Approved/Adopted: New Rule: Filed: July 21, 1993; effective August 25, 1993. Amended: Filed July 21, 1995; effective August 25, 1995. Amended: Filed November 20, 1997; effective December 25, 1997. Amended: Filed July 26, 1999; effective August 30, 1999. Amended: Filed November 13, 2007; effective December 18, 2007. Amended (Rule Number Only): Filed October 15, 2008; effective November 19, 2008. Certified Rule Filed December 20, 2021. Effective Date: February 13, 2022.



EXHIBIT E

ALABAMA STATE BOARD OF MEDICAL EXAMINERS

WILLIAM M. PERKINS, EXECUTIVE DIRECTOR

P.O. BOX 946
MONTGOMERY, ALABAMA 36101-0946
848 WASHINGTON AVE.
MONTGOMERY, ALABAMA 36104

TELEPHONE: (334) 242-4116
E MAIL: bme@albme.gov

MEMORANDUM

To: Medical Licensure Commission
From: Mandy Ellis
Date: July 20, 2023
Re: Administrative Rules Approved for Publication

The Board of Medical Examiners, at its meeting July 20, 2023, approved the following rule to be published for public comment in the *Alabama Administrative Monthly*:

- Administrative Rule 540-X-4-.07, *Emergency Prescription Refill*

The Joint Committee on Pharmacy Collaborative Practice considered changes to the joint emergency prescription refill rule that would update and clarify several provisions, including allowing the smallest dispensable package size if a 72-hour supply is not readily available and removing the extremely long list in favor of a general definition of authorized emergency medications.

These amendments are being considered by the Board of Pharmacy on July 26, 2023, which is past the filing deadline for July 2023. Therefore, if approved by both boards, the expected publication date is August 31, 2023. The public comment period ends October 5, 2023.

The proposed amendments along with any comments received will be brought back to the agencies' October meetings and then published in the November *Alabama Administrative Monthly* with an anticipated effective date of January 14, 2024.

Attachments:

Administrative Rule 540-X-4-.07, *Emergency Prescription Refill*

540-X-4-.07 Emergency Prescription Refill

(1) If a pharmacist receives a request for a prescription refill, ~~the original of which is maintained in the pharmacy files, and the pharmacist is unable to readily obtain~~ refill authorization from the prescriber, the pharmacist may dispense a one-time emergency refill of up to a 72 hour supply of the prescribed medication or the smallest dispensable package size if a 72 hour supply is not readily available, provided that under the following conditions:

(a) The prescription is not a medicinal agent listed in Schedule I or II appearing in pursuant to Title 20, Chapter 2, or the controlled substance list for Schedule I or II maintained by the State Board of Health.

~~(b) The prescription is not a medicinal agent listed in Schedule III appearing in Title 20 Chapter 2.~~

~~(c) The medication is essential to the maintenance of life or the continuation of therapy in a chronic condition including but not limited to drugs listed in the following categories, according to the latest edition of Facts and Comparisons, U.S.P./N.F., P.D.R. or A.M.A. Drug evaluation:~~

~~1. Blood Modifiers~~

~~(i) Iron Products~~

~~(I) Oral Iron~~

~~(II) Parenteral Iron~~

~~(III) Iron Combinations (with Vitamins, with Liver, with B12 and Intrinsic Factor)~~

~~(ii) Folic Acid~~

- ~~_____ (I) Leucovorin Calcium~~
- ~~_____ (iii) Vitamin B12~~
- ~~_____ (I) Cyanocobalamin~~
- ~~_____ (II) Hydroxocobalamin~~
- ~~_____ (III) Liver Preparations~~
- ~~_____ (iii) Vitamin K~~
- ~~_____ (iv) Recombinant Human Erythropoietin~~
- ~~_____ (v) Colony Stimulating Factors~~
- ~~_____ (I) Filgrastim~~
- ~~_____ (II) Sargramostim~~
- ~~_____ (vi) Antiplatelet Agents~~
- ~~_____ (I) Dipyridamole~~
- ~~_____ (II) Ticlopidine~~
- ~~_____ (vii) Anticoagulants~~
- ~~_____ (I) Heparin~~
- ~~_____ (II) Coumarin and Indandione Derivatives~~
- ~~_____ (viii) Heparin Antagonist~~
- ~~_____ (I) Protamine Sulfate~~
- ~~_____ (ix) Tissue Plasminogen Activator~~
- ~~_____ (x) Thrombolytic Enzymes~~
- ~~_____ (xi) Hemorheologic Agent~~
- ~~_____ (xii) Antithrombin~~
- ~~_____ (xiii) Antihemophilic Products~~

- _____ (I) _____ Antihemophilic factor
- _____ (II) _____ Anti-inhibitor coagulant complex
- _____ (III) _____ Factor IX complex (Human)
- _____ (xiv) Hemostatics
- _____ (I) _____ Systemic
- _____ (II) _____ Topical
- _____ (xv) _____ Plasma Protein Fractions
- _____ (xvi) _____ Dextran Adjunct
- _____ (xvii) _____ Plasma Expanders
- _____ (xviii) _____ Perfluorochemical Emulsion
- _____ (xix) _____ Hemin

_____ 2. _____ Hormones

- _____ (i) _____ Sex Hormones
- _____ (I) _____ Estrogens
- _____ (II) _____ Progestins
- _____ (III) _____ Estrogens and Progestins, Combines
- _____ (IV) _____ Oral Contraceptives
- _____ (V) _____ Levonorgestrel Implant
- _____ (VI) _____ Intrauterine Progesterone
- _____ (VII) _____ Androgens
- _____ (VIII) _____ Anabolic Steroids
- _____ (IX) _____ Estrogen and Androgen Combinations

- _____ (X) Ovulation Stimulants
- _____ (XI) Gonadotropins
- _____ (XII) Chorionic Gonadotropin
- _____ (XIII) Gonadotropin-Releasing Hormones
- _____ (XIX) Danazol
- _____ (ii) Growth Hormone
- _____ (iii) Pituitary (Growth Hormone) Test
- _____ (iv) Octreotide Acetate
- _____ (v) Posterior Pituitary Hormones
- _____ (I) Vasopressin Derivatives
- _____ (II) Oxytocics
- _____ (vi) Uterine Relaxant
- _____ (vii) Abortifacients
- _____ (I) Prostaglandins
- _____ (II) Sodium Chloride
- _____ (viii) Adrenal Cortical Steroids
- _____ (I) Corticotropin (ACTH)
- _____ (II) Mineralocorticoids
- _____ (III) Glucocorticoids
- _____ (ix) Adrenal Steroid Inhibitors
- _____ (x) Pituitary Function Test
- _____ (xi) Antidiabetic Agents
- _____ (I) Insulin

- _____ (II) _____ Sulfonylureas
- _____ (xi) _____ Glucose Elevating Agents
- _____ (I) _____ Glucagon
- _____ (II) _____ Diazoxide
- _____ (III) _____ Glucose
- _____ (xii) _____ Alglucerase
- _____ (xiii) _____ Thyroid Drugs
- _____ (I) _____ Thyroid Hormones
- _____ (II) _____ Iodine Products
- _____ (III) _____ Antithyroid Agents
- _____ (xix) _____ Calcitonin
- _____ (xv) _____ Etidronate Disodium
- _____ (xvi) _____ Gallium Nitrate

3. _____ Diuretics and Cardiovasculars

- _____ (i) _____ Diuretics
- _____ (I) _____ Carbonic Anhydrase Inhibitors
- _____ (II) _____ Thiazides and Related Diuretics
- _____ (III) _____ Loop Diuretics
- _____ (IV) _____ Potassium Sparing Diuretics
- _____ (V) _____ Diuretic Combinations
- _____ (VI) _____ Osmotic Diuretics
- _____ (VII) _____ Nonprescription Diuretics

- ~~_____ (ii) Cardiac Glycosides~~
- ~~_____ (iii) Amrinone~~
- ~~_____ (iv) Antianginal Agents~~
- ~~_____ (I) Combinations~~
- ~~_____ (v) Antiarrhythmic Agents~~
- ~~_____ (vi) Calcium Channel Blocking Agents~~
- ~~_____ (vii) Peripheral Vasodilators~~
- ~~_____ (I) Combinations~~
- ~~_____ (viii) Drugs used in Shock~~
- ~~_____ (ix) Beta-Adrenergic Blocking Agents~~
- ~~_____ (x) Alpha-Beta Adrenergic Blocking Agents~~
- ~~_____ (xi) Antihypertensives~~
- ~~_____ (I) Antiadrenergic Agents~~
- ~~_____ I. Centrally Acting~~
- ~~_____ II. Peripherally Acting~~
- ~~_____ (II) Vasodilators~~
- ~~_____ (III) Angiotensin-Converting Enzyme Inhibitors~~
- ~~_____ (IV) Agents for Pheochromocytoma~~
- ~~_____ (V) Agents for Hypertensive Emergencies~~
- ~~_____ (VI) Miscellaneous Agents~~
- ~~_____ (VII) Combinations~~
- ~~_____ (xii) Potassium Removing Agents~~
- ~~_____ (xiii) Cardioplegia Solution~~

- _____ (xix) Salt Substitutes
- _____ (xv) Edentate Disodium
- _____ (xvi) Antihyperlipidemic Agents

_____ 4. _____ Respiratory Drugs

- _____ (i) Bronchodilators
- _____ (I) Sympathomimetics
- _____ (II) Xanthine Derivatives
- _____ (ii) Respiratory Inhalant Products
- _____ (I) Corticosteroids
- _____ (II) Acetylcysteine
- _____ (III) Atropine Sulfate
- _____ (IV) Ipratropium Bromide
- _____ (V) Cromolyn Sodium
- _____ (iii) Nasal Decongestants
- _____ (I) Combinations
- _____ (iv) Intranasal Steroids
- _____ (v) Alpha Proteinase Inhibitor
- _____ (vi) Antihistamines
- _____ (I) Miscellaneous Preparations
- _____ (II) Combined Preparations
- _____ (vii) Antitussives
- _____ (I) Narcotic

- ~~_____ (II) Non-narcotic~~
- ~~_____ (viii) Expectorants~~
- ~~_____ (I) Miscellaneous Preparations~~
- ~~_____ (ix) Respiratory Combination Products~~
- ~~_____ (I) Anti-asthmatic Combinations~~
 - ~~_____ I. Xanthine Combinations~~
 - ~~_____ A. Capsules and Tablets~~
 - ~~_____ B. Liquids~~
 - ~~_____ II. Xanthine Sympathomimetic Combinations~~
 - ~~_____ A. Capsules and Tablets~~
 - ~~_____ B. Liquids~~
- ~~_____ (x) Upper Respiratory Combinations~~
 - ~~_____ (I) Decongestant Combinations~~
 - ~~_____ (II) Antihistamine and Analgesic Combinations~~
 - ~~_____ (III) Decongestants and Antihistamines~~
 - ~~_____ I. Sustained Release~~
 - ~~_____ II. Capsules and Tablets~~
 - ~~_____ III. Liquids~~
 - ~~_____ IV. Miscellaneous~~
 - ~~_____ (IV) Decongestant, Antihistamine and Analgesic Combinations~~
 - ~~_____ (V) Decongestant, Antihistamine and Anticholinergic Combinations~~
 - ~~_____ (VI) Cough Preparations~~
 - ~~_____ I. Antitussive Combinations~~

- _____ A. _____ Capsules and Tablets
- _____ B. _____ Liquids
- _____ II. _____ Expectorant Combinations
- _____ A. _____ Capsules and Tablets
- _____ B. _____ Liquids
- _____ III. _____ Antitussives and Expectorants
- _____ A. _____ Narcotic
- _____ B. _____ Non-narcotic
- _____ IV. _____ Antitussive and Expectorant Combinations
- _____ A. _____ With Decongestants
- _____ B. _____ With Antihistamines
- _____ C. _____ With Decongestants and Antihistamines
- _____ V. _____ Pediatric Cough Preparations

- _____ 5. _____ Central Nervous System Drugs
- _____ (i) _____ CNS Stimulants
- _____ (I) _____ Analeptics
- _____ (II) _____ Amphetamines
- _____ (III) _____ Anorexiant
- _____ (IV) _____ Non-prescription Diet Aids
- _____ (ii) _____ Analgesics
- _____ (I) _____ Narcotic Agonist Analgesics
- _____ (II) _____ Narcotic Analgesic Combinations

- _____ (III) _____ Narcotic Agonist-Antagonist Analgesics
- _____ (IV) _____ Other Central Analgesics
- _____ (V) _____ Acetaminophen
- _____ (VI) _____ Salicylates
- _____ (VII) _____ Non-narcotic Analgesic Combinations
- _____ (VIII) _____ Nonsteroidal Anti-Inflammatory Agents
- _____ (IX) _____ Antirheumatic Agents
- _____ (X) _____ Agents for Gout
- _____ (XI) _____ Agents for Migraine
- _____ I. _____ Combinations
- _____ (iii) _____ Antiemetic/Antivertigo Agents
- _____ (iv) _____ Psychotherapeutic Drugs
- _____ (I) _____ Antianxiety Agents
- _____ (II) _____ Antidepressants
- _____ (III) _____ Antipsychotic Agents
- _____ (IV) _____ Miscellaneous Psychotherapeutic Agents
- _____ (V) _____ Sedative and Hypnotic
- _____ (VI) _____ Non-barbiturates
- _____ (VII) _____ Nonprescription Sleep Aids
- _____ (VIII) _____ Barbiturates
- _____ (vi) _____ General Anesthetics
- _____ (I) _____ Barbiturates
- _____ (II) _____ Non-barbiturates

_____ (iii) — Gases

_____ (iv) — Volatile Liquids

_____ (vii) — Anticonvulsant

_____ (viii) — Muscle Relaxants

_____ (i) — Adjuncts to Anesthesia

_____ (ii) — Skeletal

_____ (iii) — Combinations

_____ (ix) — Anti parkinson Agents

6. ~~Gastrointestinal Drugs~~

_____ (i) — Antacids

_____ (i) — Combinations

_____ (ii) — Sucralfate

_____ (iii) — Gastrointestinal Anticholinergic/Antispasmodics

_____ (i) — Combinations

_____ (iv) — Histamine H₂ Antagonists

_____ (v) — Prostaglandins

_____ (vi) — Antiflatulents

_____ (vii) — GI Stimulants

_____ (i) — Metoclopramide

_____ (ii) — Dexpanthanol

_____ (viii) — Digestive Enzymes

_____ (ix) — Gastric Acidifiers

- (x) — Choleretics
- (xi) — Hydrocholeretics
- (I) — Combinations
- (xii) — Miscellaneous Digestive Products
- (xiii) — Gallstone Solubilizing Agents
 - (I) — Chenodiol
 - (II) — Ursodiol
 - (III) — Monoctanoic
- (xiv) — Laxatives
 - (I) — Saline
 - (II) — Stimulant
 - (III) — Bulk
 - (IV) — Emollient
 - (V) — Fecal Softeners
 - (VI) — Hyperosmolar Agents
 - (VII) — Enemas
 - (VIII) — CO₂ Releasing Suppositories
 - (IX) — Bowel Evacuants
 - (X) — Lactulose
 - (XI) — Combinations
 - (XV) — Antidiarrheal
 - (I) — Diphenoxylate/Atropine
 - (II) — Loperamide

_____ (III) Bismuth Subsalicylate

_____ (IV) Combinations

_____ (xvi) Mesalamine

_____ 7. Antineoplastic Agents

_____ (i) Chemotherapeutic Regimens

_____ (ii) Alkylating Agents

_____ (I) Nitrogen Mustards

_____ I. Mechlorethamine HCl

_____ II. Chlorambucil

_____ III. Cyclophosphamide

_____ IV. Uracil Mustard

_____ (II) Nitrosoureas

_____ I. Lomustine

_____ II. Carmustine

_____ III. Streptozocin

_____ (III) Thiotepa

_____ (IV) Busulfan

_____ (V) Pipobroman

_____ (VI) Cisplatin

_____ (iii) Antimetabolite

_____ (I) Methotrexate

_____ (II) Fluorouracil and Floxuridine

- _____ (III) Cytarabine
- _____ (IV) Mercaptopurine
- _____ (V) Thioguanine
- _____ (iv) Hormones
- _____ (I) Androgens
- _____ I. Testolactone
- _____ (II) Progestins
- _____ I. Megestrol Acetate
- _____ II. Medroxyprogesterone Acetate
- _____ (III) Estrogens
- _____ I. Diethylstilbestrol Diphosphate
- _____ II. Polyestradiol Phosphate
- _____ (IV) Estrogen/Nitrogen Mustard
- _____ I. Estramustine Phosphate
- _____ (V) Anti-estrogen
- _____ I. Tamoxifen
- _____ (VI) Gonadotropin Hormone-Releasing Antigen
- _____ I. Leuprolide Acetate
- _____ (v) Antibiotics
- _____ (I) Bleomycin Sulfate
- _____ (II) Doxorubicin HCl
- _____ (III) Daunorubicin HCl
- _____ (IV) Mitoxantrone HCl

- _____ (V) Mitomycin
- _____ (VI) Dactinomycin
- _____ (VII) Picamycin
- _____ (vi) Mitotic Inhibitors
- _____ (I) Etoposide
- _____ (II) Vincristine Sulfate
- _____ (III) Vinblastine Sulfate
- _____ (vi) Radiopharmaceutical
- _____ (I) Sodium Iodide I
- _____ (II) Sodium Phosphate P
- _____ (III) Chromic Phosphate P
- _____ (vii) Miscellaneous
- _____ (I) Interferon Alfa-2a
- _____ (II) Interferon Alfa-2b
- _____ (III) Hydroxyurea
- _____ (IV) Procarbazine HCl
- _____ (V) Dacarbazine
- _____ (VI) Mitotane
- _____ (VII) Asparaginase
- _____ (viii) NCI Investigational Agents

_____ (b) The medication is essential to the maintenance of life or the continuation of therapy and in the pharmacist's professional judgement, the interruption of therapy

might reasonably produce undesirable health consequences or may cause physical or mental discomfort.

____(c) The pharmacist has a record of a prescription at the pharmacy or has been presented proof of a prescription filled within the last 90 days in the name of the patient for whom the request of the emergency supply is being made.

____(d) A pharmacist or pharmacy shall not dispense or sell the same drug to the same patient, as provided in this section, more than one time in any 12-month period.

____(e) The pharmacist must inform the patient or the patient's representative at the time of dispensing that the refill is being provided without the practitioner's authorization, and that practitioner authorization is required for any future refill.

____(df) The dispensing pharmacist shall creates a written prescription order containing all of the prescription information required by federal and state statutes, rules and regulations and shall also include the statement "Emergency Fill".

(eg) The dispensing pharmacist shall ~~notifiesy~~ the prescriber, orally or in writing, of the emergency dispensing within ~~seventy-two~~ twenty-four (24) hours after such dispensing.

(2) This rule is adopted jointly by the Board of Pharmacy and the Board of Medical Examiners.

Author: Alabama Board of Medical Examiners.

Statutory Authority: § 34-23-75 and §34-24-53, Code of Alabama 1975.

History: Filed: December 17, 1992 (for publication). Refiled for Publication: August 11, 1993. Approved/Adopted: October 20, 1993. Effective Date: November 25, 1993. (This rule has been jointly adopted by the BME and the Pharmacy Board.)



EXHIBIT F

ALABAMA STATE BOARD OF MEDICAL EXAMINERS

WILLIAM M. PERKINS, EXECUTIVE DIRECTOR

P.O. BOX 946
MONTGOMERY, ALABAMA 36101-0946
848 WASHINGTON AVE.
MONTGOMERY, ALABAMA 36104

TELEPHONE: (334) 242-4116
E MAIL: bme@albme.gov

MEMORANDUM

To: Medical Licensure Commission
From: Mandy Ellis
Date: July 20, 2023
Re: Administrative Rules Approved for Publication

The Board of Medical Examiners, at its meeting July 20, 2023, approved the following rules to be published for public comment in the *Alabama Administrative Monthly*:

- Administrative Rule 540-X-26-.01, *Definitions*
- Administrative Rule 540-X-26-.04, *Collaborative Drug Therapy Management Agreement: Required Terms*
- Administrative Rule 540-X-26-.05, *Limitations*
- Administrative Rule 540-X-26-.06, *Standards for Physicians*
- Administrative Rule 540-X-26-.07, *Standards for Pharmacists*

At its June 2023, meeting, the Joint Committee on Pharmacy Collaborative Practice voted to present the attached rule amendments that permit authorized pharmacists to test, screen for, and treat acute, uncomplicated illnesses or injuries, including influenza and streptococcus.

These amendments are being considered by the Board of Pharmacy on July 26, 2023, which is past the filing deadline for July 2023. Therefore, if approved by both boards, the expected publication date is August 31, 2023. The public comment period ends October 5, 2023.

The proposed amendments along with any comments received will be brought back to the agencies' October meetings and then published in the November *Alabama Administrative Monthly* with an anticipated effective date of January 14, 2024.

Attachments:

Administrative Rule 540-X-26-.01, *Definitions*

**Administrative Rule 540-X-26-.04, *Collaborative Drug Therapy Management Agreement:
Required Terms***

Administrative Rule 540-X-26-.05, *Limitations*

Administrative Rule 540-X-26-.06, *Standards for Physicians*

Administrative Rule 540-X-26-.07, *Standards for Pharmacists*

540-X-26-.01 Definitions.

(1) The following definitions are applicable to collaborative drug therapy management:

(a) "Agreement" means the Collaborative Drug Therapy Management Agreement.

(b) "Board of Medical Examiners" means the State Board of Medical Examiners established pursuant to Ala. Code § 34-24-53.

(c) "Board of Pharmacy" means the State Board of Pharmacy established pursuant to Ala. Code § 34-23-90.

(d) "Collaborative Drug Therapy Management" means the practice of pharmacy whereby an individual pharmacist licensed in this state jointly and voluntarily works with an individual physician licensed in this state under a Collaborative Drug Therapy Management Agreement to provide a range of services to a patient of the Collaborating Physician and the Collaborating Pharmacist intended to optimize therapeutic outcomes; detect and prevent adverse medication interactions and side effects; provide education on the patient's medications used to treat the disease state so that medications are taken correctly; monitor, modify, and discontinue drug therapy as directed by the physician; provide education on managing medication side effects; communicate with third party payors and insurers regarding prior authorization for prescription medications; and any other activity or service specified in a protocol approved by both the Board of Medical Examiners and the Board of Pharmacy, or otherwise authorized by this Chapter.

(e) "Collaborating Pharmacist" means a pharmacist who is licensed to practice pharmacy in Alabama, who is a party to a Collaborative Drug Therapy Management

Agreement, and who has a direct pharmacist-patient relationship with the patient served by the Agreement.

(f) "Collaborating Physician" means a doctor of medicine or a doctor of osteopathy licensed to practice medicine in Alabama who is a party to a Collaborative Drug Therapy Management Agreement, who has a direct physician-patient relationship, or otherwise authorized by this Chapter, with the patient served by the Agreement, and who has prepared the patient-specific, drug or drug class-specific, disease-specific, and condition-specific plan of care based on a physical examination of the patient where required under this Chapter.

(g) "Covering Pharmacist" means a pharmacist licensed to practice pharmacy in Alabama who agrees in writing to be readily available to fulfill the duties of a Collaborating Pharmacist pursuant to a Collaborative Drug Therapy Management Agreement during the absence of the Collaborating Pharmacist. The Covering Pharmacist shall be an employee of the same pharmacy practice as the Collaborating Pharmacist, demonstrate the ability to provide the services listed in the Agreement, and abide by the rules and regulations of the Board of Medical Examiners and Board of Pharmacy.

(h) "Covering Physician" means a doctor of medicine or a doctor of osteopathy licensed to practice medicine in Alabama who agrees in writing to be readily available to fulfill the duties of a Collaborating Physician pursuant to a Collaborative Drug Therapy Management Agreement during the absence of the Collaborating Physician. The covering physician shall be either a member of the same medical practice, practice group, or multidisciplinary medical team, or of the same or similar practice specialty as the

Collaborating Physician and shall abide by the rules and regulations adopted by the Board of Medical Examiners and Board of Pharmacy.

(i) "Formulary" means a list of legend drugs or drug classes that may be utilized under a Collaborative Drug Therapy Management Agreement.

(j) "Joint Committee" means the Joint Committee on Pharmacy Collaborative Practice, established for the purpose of enabling a mechanism for the exchange of information between the Board of Medical Examiners and the Board of Pharmacy on matters related to physician-pharmacist collaboration.

(k) "Licensed Healthcare Facility" means a hospital, as defined in Ala. Code § 22-21-20(1), licensed by the Alabama Department of Public Health, or a Federally Qualified Health Center, as defined by ALA. ADMIN. CODE r. 560-X-48-.01(1).

(l) "Patient Care Services" means services rendered by Collaborating Physicians and Collaborating Pharmacists for the benefit of the patient and which must be within the professional training and experience of the Collaborating Physician and Collaborating Pharmacist and be covered by the Collaborative Drug Therapy Management Agreement.

(m) "Protocol" means a document approved by the Board of Medical Examiners and Board of Pharmacy establishing the permissible functions and activities to be performed by a Collaborating Pharmacist and signed by the parties to the Collaborative Drug Therapy Management Agreement.

(n) "Quality Assurance" means documented evaluation by the Collaborating Physician of the parties' adherence to the Agreement and patient outcomes against defined quality outcome measures, using a selected, meaningful sample of patient

records, which will identify outcomes needing improvement, set performance goals, and assess progress towards meeting established goals, with a summary of findings, conclusions, and, if indicated, recommendations for change. The physician's signature on the patient record does not constitute quality assurance monitoring.

(o) "Routine Scope of Practice and Services" means any patient care service provided by the Collaborating Physician and his or her practice in compliance with his or her medical education, training, experience, and the Board of Medical Examiners' laws, rules, policies, and procedures, and that of the collaborating pharmacist and his or her practice in compliance with his or her pharmacy education, training, experience, and the Board of Pharmacy's laws, rules, policies, and procedures.

(p) "Unrestricted," for the purpose of this Chapter, means an active pharmacy permit, pharmacy Drug Enforcement Administration (DEA) registration, pharmacist license, medical license, and Alabama Controlled Substances Certificate that is not revoked, suspended, or on probation at the time of application and is not subject to any conditions, restrictions, or limitations imposed by the applicable licensing board which relate directly to the delivery of health care services. A condition, restriction, or limitation directly relates to the delivery of health care services when it prevents a provider from treating certain types of patients or certain types of ailments or injuries, or otherwise limits a provider from fully engaging in the practice which would otherwise be authorized pursuant to his or her license.

(q) "Acute uncomplicated illness or injury" means a recent or new short-term problem with low risk of morbidity for which treatment is considered and full recovery

without functional impairment is expected. For the purposes of this section, an acute, uncomplicated illness or injury includes:

(a) Influenza.

(b) Streptococcus.

(c) Any other condition as recommended by the Joint Committee.

Under this definition, a pharmacist may use any tests which the Centers for Medicare and Medicaid Services has determined qualifies for a waiver under the federal Clinical Laboratory Improvement Amendments of 1988, or the federal rules adopted thereunder, or any established screening procedures that can safely be performed by a pharmacist.

Author: Alabama Board of Medical Examiners

Statutory Authority: Ala. Code § 34-24-53; Act 2019-368 (Ala. Code § 34-23-77)

History: Approved for publication: April 15, 2021. Certified Rule Filed August 20, 2021. Effective Date: October 15, 2021.

540-X-26-.04 Collaborative Drug Therapy Management Agreement: Required Terms.

(1) Each Agreement shall contain the following elements, at a minimum:

(a) Names and Titles of Collaborating Providers. The Agreement must contain identification of the Collaborating Pharmacist, the Collaborating Physician, Covering Physician(s), and Covering Pharmacist(s) who are parties ("collaborating providers") to the Agreement. The Agreement shall state the procedure to be followed to indicate changes in the collaborating providers participating in the Agreement. Unless expressly stated in the Agreement, changes to the list of collaborating providers bound by the Agreement shall not automatically void the Agreement. Signatures may be handwritten, electronic, or any other method authorized by the Board of Pharmacy and the Board of Medical Examiners.

(b) Authorized Care and Services. The Agreement must contain an "Authorized Care and Services" section defining the nature and scope of patient care services and activities, including screening, prevention, assessment, management, and care, authorized or restricted, to be provided by the Collaborating Pharmacist pursuant to approved Protocol(s) under the Agreement. All care and services to be provided shall be within the routine scope of practice and services delivered by the Collaborating Physician; provided, however, that the authorized care and services may not be broader in scope than the permissible functions and activities authorized under the Collaborating Pharmacist's license, training, experience, and Board of Pharmacy's laws, rules, policies, and procedures. All care and services provided, with the exception of immunizations, opioid antagonists, and ~~screening or testing which do not require such patient-specific plans~~ acute, uncomplicated illness or injury, must be pursuant to a diagnosis appropriately

made and documented by the Collaborating Physician. An Agreement which includes a Protocol authorizing the Collaborating Pharmacist to modify or discontinue drug therapy must include specific authorization in the authorized care and services portion of the Agreement and must contain a Formulary that may be modified or discontinued by the Collaborating Pharmacist under the terms of the Agreement.

(c) Documentation and Communication.

1.____The Collaborating Physician shall be responsible for documenting the communication in the patient medical record maintained by the Collaborating Physician. The Collaborating Physician shall, within 24 hours, communicate to the Collaborating Pharmacist any changes initiated to a patient's drug therapy that is subject to an Agreement; a written, telephonic, or electronic prescription which contains specific dosage information may satisfy this requirement. The collaborating pharmacist shall, within 24 hours, communicate to the collaborating physician and any physician(s) designated by the patient any changes to a patient's drug therapy and/or individual patient care services as set out in the Agreement. The Agreement shall describe the methods for documenting the patient medical record by the Collaborating Pharmacist and the Collaborating Physician, for documentation of services performed pursuant to the Agreement, and for communication and feedback between the Collaborating Pharmacist and the Collaborating Physician. All such records shall be maintained by the Collaborating Physician for a period of not less than six (6) years from the date of the last patient contact, or if the patient is a minor, the record shall be maintained for a period of not less than eight (8) years from the date of the last patient contact. All such records shall be

maintained by the Collaborating Pharmacist within the employing pharmacy for a period of not less than two (2) years from the date of the last patient contact.

2. A pharmacist performing testing or screening for and treatment of acute, uncomplicated illness or injury conditions shall also:

(i) Provide each patient with written information to advise the patient to seek follow-up care from either a physician with whom the patient has a pre-existing relationship, or, if no pre-existing relationship exists, to seek follow-up care from the collaborating physician.

(ii) Provide the patient with a consent form allowing any changes to a patient's drug therapy and/or individual patient care services as set out in the Agreement to be provided to the collaborating physician and the physician with whom the patient has a pre-existing relationship.

(d) **Override Clause.** A provision must be included in the Agreement providing for the Collaborating Physician to override the actions taken by the Collaborating Pharmacist specific to services provided under the Agreement. This provision must state how such overrides shall be documented and communicated to the Collaborating Pharmacist and the patient in a timely manner, as defined in the Agreement.

(e) **Expiration, Modification, and Termination.** The effective date of the Agreement shall be stated in the Agreement. Each Agreement must contain a term or expiration date upon which the Agreement will expire if not renewed; however, in any event, all Agreements must be reviewed, updated where applicable, and renewed at least every two (2) years as evidenced by signatures of the parties. Every Agreement must contain a provision stating the process for modification or termination of the Agreement

by any of the parties. An Agreement may be amended upon mutual approval by the Collaborating Physician and Collaborating Pharmacist who have been duly authorized to execute, modify, or change the Agreement. Such amendments shall include, at a minimum, a description of the desired change and the effective date of the change. Any amendment executed shall not automatically void the terms and conditions of the existing Agreement unless expressly stated. Amendments to the authorized care and services which establish substantive additions or reductions to the scope of patient care services provided under the Agreement, including new therapeutic classes of drugs added to the authorized Formulary, must be provided to the Board of Pharmacy and Board of Medical Examiners no later than ten (10) days from the date the amendment is signed by the parties.

(f) Automatic Exclusions. Agreements must have a provision that identifies any terms under which a provider will be automatically excluded from participation in the Agreement, which shall include, but are not limited to: death; the suspension, surrender, revocation, or retirement of license; loss or restriction of prescriptive authority; the suspension, surrender, or revocation of a Drug Enforcement Administration registration or Alabama Controlled Substances Certificate; or exclusion from any federally-funded health programs.

(g) Quality Assurance. The Collaborating Physician and Collaborating Pharmacist shall engage in a quality assurance review of the care provided for patients pursuant to the Agreement on a quarterly basis. Quality Assurance shall include, and the Agreement shall provide for, a quarterly review by the Collaborating Physician of a meaningful sample of patient records. A “meaningful sample” shall consist of:

1. Not less than twenty-five percent (25%) of the patients treated pursuant to the Agreement for the first two years of the Agreement;

2. Not less than ten percent (10%) of the patients treated pursuant to the Agreement after the Agreement has been in effect for two years; and

3. All adverse outcomes of the patients treated pursuant to the Agreement. The quality assurance review shall be properly documented, retained by the participating parties of the Agreement, and available for review by representatives of the Board of Medical Examiners for at least five (5) years and the Board of Pharmacy for at least two (2) years.

(h) All Agreements shall require the Collaborating Pharmacist to use an area for in-person or other approved consultations with patients that ensures the confidentiality of the communication and complies with the requirements and standards set forth by the Board of Pharmacy in ALA. ADMIN. CODE r. 680-X-2-.27.

(i) Notice. All Agreements shall include a provision stating which party or parties shall bear the costs and responsibility of promptly notifying affected individuals in the event that an Agreement expires or is terminated. All Agreements shall specify when patients served by an Agreement are to be notified of changes to the Agreement. Any provision of the Agreement notwithstanding, the patients served by an Agreement shall be promptly notified when a Collaborating Physician or Collaborating Pharmacist departs from or is terminated from an Agreement, and said notice shall include the Collaborating Physician's or Collaborating Pharmacist's contact information as well as instructions for how patients may obtain copies of their records or have them forwarded to the physician or pharmacist of their choice.

(2) Agreements that include the testing or screening for and treatment of acute, uncomplicated illness or injury shall also include:

(a) Patient selection criteria, which shall include the physician's instructions for obtaining relevant patient medical history for the purpose of identifying disqualifying health conditions, adverse reactions, and contraindications to the approved course of treatment.

(b) Treatment protocols, which shall include the physician's instructions for the treatment of acute, uncomplicated illness or injury based on the patient's age, symptoms, and test results, including negative results.

(c) Any other requirements as established by the Board of Pharmacy and Board of Medical Examiners.

Author: Alabama Board of Medical Examiners

Statutory Authority: Ala. Code § 34-24-53; Act 2019-368 (Ala. Code § 34-23-77)

History: Approved for publication: April 15, 2021. Certified Rule Filed August 20, 2021. Effective Date: October 15, 2021.

540-X-26-.05 Limitations.

(1) The scope of an Agreement shall NOT include:

(a) Any person or patient of a Collaborating Physician for whom such Collaborating Physician has not prepared a patient-specific, drug- or drug class-specific, disease-specific, or condition-specific plan of care based on a physical examination of the patient by the Collaborating Physician within the past twelve (12) months, with the exception of immunizations and ~~screening or testing which do not require such patient-specific plans~~ acute, uncomplicated illness or injury, as well as the dispensing of opioid antagonists as defined in Ala. Code § 20-2-280; or

(b) The prescribing of controlled substances listed or to be listed in the schedules under federal law and in Ala. Code §§ 20-2-23, 20-2-25, 20-2-27, 20-2-29, and 20-2-31 and/or ALA. ADMIN. CODE r. 420-7-2 and its Appendix.

(2) No retail pharmacy may employ a physician for the purpose of maintaining, establishing, or entering into a collaborative practice agreement. Nothing shall prohibit a retail pharmacy from hiring a physician or licensed medical practitioner for the purpose of conducting quality assurance reviews of its pharmacists that are engaged in the practice of collaborative drug therapy.

Author: Alabama Board of Medical Examiners

Statutory Authority: Ala. Code § 34-24-53; Act 2019-368 (Ala. Code § 34-23-77)

History: Approved for publication: April 15, 2021. Certified Rule Filed August 20, 2021. Effective Date: October 15, 2021.

540-X-26-.06 Standards for Physicians.

(1) Physicians engaged in an Agreement shall:

(a) Provide professional medical oversight and instruction to the Collaborating Pharmacist;

(b) Establish and/or maintain a physician-patient relationship with each patient receiving services under the Agreement, with the exception of immunization and opioid antagonists;

(c) Be readily available to the Collaborating Pharmacist through direct telecommunication for consultation, assistance, and direction, or shall make arrangements for a substitute physician to be readily available who is pre-approved by the Board of Medical Examiners, who practices in a specialty substantially similar to that of the Collaborating Physician, and who is familiar with these rules; ~~and~~

(d) Collaborate with pharmacist(s) who agree to be readily available to the physician through direction telecommunication for consultation, assistance, and collaboration; and

(e) Contact each patient receiving treatment by a pharmacist for an acute, uncomplicated illness or injury not later than five (5) days following the first day of treatment to discuss follow-up care or refer the patient for care from a physician with whom the patient has a pre-existing relationship.

(2) In the event the Collaborating Physician is not readily available, provisions shall be made for professional medical oversight and direction by a Covering Physician who is readily available, who is pre-approved by the Board of Medical Examiners, and who is familiar with these rules. The Collaborating Physician shall certify to the Board of

Medical Examiners at least annually that any approved Covering Physician continues to agree to serve in that capacity and shall inform the Board of Medical Examiners of the termination of a Covering Physician within ten (10) days of the termination.

(3) In the event of an unanticipated, permanent absence of a Collaborating Physician, a previously approved Covering Physician may be designated as a temporary Collaborating Physician for a period of up to sixty (60) days. During the sixty (60) day time period, a new Agreement designating a new Collaborating Physician should be submitted for approval.

Author: Alabama Board of Medical Examiners

Statutory Authority: Ala. Code § 34-24-53; Act 2019-368 (Ala. Code § 34-23-77)

History: Approved for publication: April 15, 2021. Certified Rule Filed August 20, 2021. Effective Date: October 15, 2021.

540-X-26-.07 Standards for Pharmacists.

(1) Pharmacists engaged in an Agreement shall:

(a) Establish and maintain a pharmacist-patient relationship with each patient receiving services under the Agreement;

(b) Be readily available to the Collaborating Physician through direct telecommunication for consultation, assistance, and direction; and

(c) Collaborate with physician(s) who agree to be readily available to the pharmacist through direct telecommunication for consultation, assistance, and collaboration.

(2) In the event the Collaborating Pharmacist is not readily available, provisions shall be made for a Covering Pharmacist who is readily available, who is pre-approved by the Board of Pharmacy, and who is familiar with these rules. The Collaborating Pharmacist shall certify to the Board of Pharmacy at least annually that any approved Covering Pharmacist continues to agree to serve in that capacity and shall inform the Board of Pharmacy of the termination of a Covering Pharmacist within ten (10) days of the termination.

(3) In the event of an unanticipated, permanent absence of a Collaborating Pharmacist, a Covering Pharmacist may be designated as a temporary Collaborating Pharmacist for a period of up to sixty (60) days. During the sixty (60) day time period, a new Agreement designating a new Collaborating Pharmacist should be submitted for approval.

(4) If performing testing or screening for and treatment of acute, uncomplicated illness or injury, a pharmacist shall also:

(a) Provide each patient with written information to advise the patient to seek follow-up care from either a physician with whom the patient has a pre-existing relationship, or, if no pre-existing relationship exists, to seek follow-up care from the collaborating physician.

(b) Upon request of a patient, furnish patient records to a physician designated by the patient.

Author: Alabama Board of Medical Examiners

Statutory Authority: Ala. Code § 34-24-53; Act 2019-368 (Ala. Code § 34-23-77)

History: Approved for publication: April 15, 2021. Certified Rule Filed August 20, 2021. Effective Date: October 15, 2021.

EXHIBIT G

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

**LAUREN ELIZABETH
DUENSING, M.D.,**

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION
OF ALABAMA**

CASE NO. 2020-381

ORDER

On July 13, 2022, the Board and Respondent filed a proposed Settlement Agreement. The Commission held a hearing on February 22, 2023 for the purpose of determining whether and how the Settlement Agreement would culminate in the final disposition of this matter. Five months on, this matter remains pending before the Commission.

Accordingly, this matter is set for a final hearing on the merits, as prescribed in Ala. Code § 34-24-360, *et seq.*, and Ala. Admin. Code Chapter 545-X-3, to be held on January 24, 2024, at 10:00 a.m., at 848 Washington Avenue, Montgomery, Alabama, 36104.

DONE on this the 1st day of August, 2023.

**THE MEDICAL LICENSURE
COMMISSION OF ALABAMA**

By:

**E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:49:46 CDT**

**Craig H. Christopher, M.D.
its Chairman**

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

JAMES STEVEN ST. LOUIS, D.O.,

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION
OF ALABAMA**

CASE NO. 2023-148

ORDER

The Commission has received information that the Respondent in this matter has withdrawn his application for reinstatement. Respondent's withdrawal of his application for reinstatement is noted, and the Administrative Complaint in this matter is dismissed without prejudice.

DONE on this the 1st day of August, 2023.

**THE MEDICAL LICENSURE
COMMISSION OF ALABAMA**

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:52:05 CDT

Craig H. Christopher, M.D.
its Chairman

EXHIBIT I

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

**RAMESH BABU PERAMSETTY,
M.D.,**

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION
OF ALABAMA**

CASE NO. 2017-305

ORDER SETTING HEARING
On Respondent's Request for Modification of Probation

The Medical Licensure Commission has received Respondent's request for modification of the term of probation imposed by our Consent Order of July 23, 2019. The Board, on July 25, 2023, filed its opposition to Respondent's request. Under the provisions of Ala. Code § 34-24-361(h)(9), this request triggers a contested case hearing. This Order shall serve as the Notice of Hearing prescribed in Ala. Admin. Code r. 545-X-3-.03(3), (4). The Commission's legal authority and jurisdiction to hold the hearing in this matter are granted by Article 8, Chapter 24, Title 34 of the Code of Alabama (1975), and the particular sections of the statutes and rules involved are as set forth in this Order.

1. Service of This Order

A copy of this Order shall be served forthwith upon the Respondent, by personally delivering the same to Respondent if he or she can be found within the State of Alabama, or, by overnight courier, signature required, to Respondent's last known address if he or she cannot be found within the State of Alabama. The Commission further directs that personal service of process shall be made by Nicole Hardy, who is designated as the duly authorized agent of the Commission.

2. Initial Hearing Date

This matter is set for a hearing as prescribed in Ala. Code §§ 34-24-360, *et seq.*, and Ala. Admin. Code Chapter 545-X-3, to be held on Wednesday, February 28, 2024, at 10:00 a.m., at 848 Washington Avenue, Montgomery, Alabama, 36104. Unless otherwise specified by the Commission, the hearing will be held in person. All parties and counsel are expected to appear and to be prepared for the hearing at this date, time, and place.

3. Appointment of Hearing Officer

The Commission appoints the Honorable William R. Gordon, Circuit Judge (Ret.) as the Hearing Officer in this matter, pursuant to Ala. Admin. Code r. 545-X-3-.08. The Hearing Officer shall exercise general superintendence over all pre-hearing proceedings in this matter, and shall serve as the presiding officer at the

hearing, having and executing all powers described in Ala. Admin. Code r. 545-X-3-.08(1)(a)-(g).

4. Rescheduling/Motions for Continuance

All parties and attorneys are expected to check their schedules immediately for conflicts. Continuances will be granted only upon written motion and only for good cause as determined by the Chairman (or, in his absence, the Vice-Chairman) of the Medical Licensure Commission. Continuances requested on grounds of engagement of legal counsel on the eve of the hearing will not be routinely granted.

5. Case Management Orders

The Hearing Officer is authorized, without further leave of the Commission, to enter such case management orders as he considers appropriate to the particular case. Among any other matters deemed appropriate by the Hearing Officer, the Hearing Officer may enter orders addressing the matters listed in Ala. Admin. Code r. 545-X-3-.03(5)(a)-(f) and/or 545-X-3-.08(1)(a)-(g). All parties will be expected to comply with such orders.

6. Manner of Filing and Serving Pleadings

All pleadings, motions, requests, and other papers in this matter may be filed and served by e-mail. All filings should be e-mailed to:

- The Hearing Officer, William Gordon (wrgordon@charter.net);

- The Director of Operations of the Medical Licensure Commission, Rebecca Robbins (rrobbins@almlc.gov);
- General Counsel of the Medical Licensure Commission, Aaron Dettling (adettling@almlc.gov);
- General Counsel for the Alabama Board of Medical Examiners, Wilson Hunter (whunter@albme.gov); and
- Respondent/Licensee or his or her counsel, as appropriate.

The Director of Operations of the Medical Licensure Commission shall be the custodian of the official record of the proceedings in this matter.

7. Discovery

Consistent with the administrative quasi-judicial nature of these proceedings, limited discovery is permitted, under the supervision of the Hearing Officer. *See* Ala. Code § 41-22-12(c); Ala. Admin. Code r. 545-X-3-.04. All parties and attorneys shall confer in good faith with one another regarding discovery. If disputes regarding discovery are not resolved informally, a motion may be filed with the Hearing Officer, who is authorized to hold such hearings as appropriate and to make appropriate rulings regarding such disputes.

8. Publicity and Confidentiality

Under Alabama law, this Order is a public document. The hearing itself is closed and confidential. The Commission's written decision, if any, will also be public. *See* Ala. Code § 34-24-361.1; Ala. Admin. Code r. 545-X-3-.03(10)(h), (11).

9. Stipulations

The parties are encouraged to submit written stipulations of matters as to which there is no basis for good-faith dispute. Stipulations can help to simplify and shorten the hearing, facilitate the Commission's decisional process, and reduce the overall costs of these proceedings. Written stipulations will be most useful to the Commission if they are submitted in writing approximately 10 days preceding the hearing. The Hearing Officer is authorized to assist the parties with the development and drafting of written stipulations.

10. Judicial Notice

The parties are advised that the Commission may take judicial notice of its prior proceedings, findings of fact, conclusions of law, decisions, orders, and judgments, if any, relating to the Respondent. *See* Ala. Code § 41-22-13(4); Ala. Admin. Code r. 545-X-3-.09(4).

11. Settlement Discussions

The Commission encourages informal resolution of disputes, where possible and consistent with public interest. If a settlement occurs, the parties should notify

the Hearing Officer, the Commission's Director of Operations, and Commission's General Counsel. The terms of settlement are subject to the approval of the Commission. If approved, the Commission will generally incorporate the settlement terms into a Consent Decree.

12. Subpoenas

The Commission has the statutory authority to compel the attendance of witnesses, and the production of books and records, by the issuance of subpoenas. *See* Ala. Code §§ 34-24-363; 41-22-12(c); Ala. Admin. Code r. 545-X-3-.05. The parties may request that the Hearing Officer issue subpoenas for witnesses and/or documents, and the Hearing Officer is authorized to approve and issue such subpoenas on behalf of the Commission. Service of such subpoenas shall be the responsibility of the party requesting such subpoenas.

13. Hearing Exhibits

- A. Parties and attorneys should, if possible, stipulate as to the admissibility of documents prior to the hearing.
- B. The use of electronic technology, USB drives, CD's, DVD's, etc. is acceptable and encouraged for voluminous records. If the Commission members will need their laptop to view documents, please notify the Hearing Officer prior to your hearing.
- C. If providing hard copies, voluminous records need not be copied for everyone but, if portions of records are to be referred to, those portions should be copied for everyone.

- D. If a document is to be referred to in a hearing, copies should be available for each Commission member, the Hearing Officer, the Commission's General Counsel, opposing attorney, and the court reporter (12 copies).
- E. Index exhibits/documents for easy reference.
- F. Distribute exhibit/document packages at the beginning of the hearing to minimize distractions during the hearing.

14. Appeals

Appeals from final decisions of the Medical Licensure Commission, where permitted, are governed by Ala. Code § 34-24-367.

DONE on this the 1st day of August, 2023.

THE MEDICAL LICENSURE
COMMISSION OF ALABAMA

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:49:17 CDT

Craig H. Christopher, M.D.
its Chairman

Distribution:

- Honorable William R. Gordon (incl. Respondent's written request and Board Opposition)
- Rebecca Robbins
- Respondent/Respondent's Attorney
- E. Wilson Hunter
- Aaron L. Dettling

EXHIBIT J

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

JANIE T. BUSH TESCHNER, M.D.,

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION OF
ALABAMA**

CASE NO. 2020-324

ORDER

This matter comes before the Medical Licensure Commission of Alabama on the proposed practice plan submitted by Respondent on July 10, 2023, and supplemented on July 26, 2023. Respondent's counsel appeared and presented information about the practice plan on July 27, 2023.

Respondent's proposed practice plan includes two employment possibilities: (a) employment with the Social Security Administration in Mobile, Alabama performing disability reviews, or (b) employment with Signify Health performing home health checks for Medicare Advantage plans.

Upon review, to the extent that either of these employment opportunities would not satisfy the requirements of Paragraph 3(d) of our Order of April 19, 2023, those requirements are waived as to the proposed practice plan currently before the Commission.

Upon consideration, Respondent's proposed practice plan is approved, with the following stipulations: (1) Respondent must advise the Board's Physician Monitor immediately upon commencing employment, and shall provide the name of Respondent's workplace monitor as required by Paragraph 3(o) of our Order of April 19, 2023; (2) within six months of commencing employment, Respondent shall demonstrate significant progress toward full compliance with all provisions of the Order; and (3) starting no later than six months after commencing employment, Respondent shall make monthly status reports to the Board's Physician Monitor.

DONE on this the 3rd day of August, 2023.

THE MEDICAL LICENSURE
COMMISSION OF ALABAMA

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-03 11:14:05 CDT

Craig H. Christopher, M.D.
its Chairman

EXHIBIT K

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

WILLIAM H. BARTON, III, M.D.,

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION OF
ALABAMA**

CASE NO. 2023-159

CONSENT DECREE

This matter comes before the Medical Licensure Commission of Alabama (“the Commission”) on the Administrative Complaint (“the Administrative Complaint”) filed by the Alabama State Board of Medical Examiners (“the Board”) on July 11, 2023. The Board and the Respondent, William H. Barton, III, M.D. (“Respondent”), have entered into a Joint Settlement Agreement (“the Settlement Agreement”), and have asked the Commission to approve the Settlement Agreement and to embody it in this Consent Decree.

General Provisions

1. **Approval of the Settlement Agreement.** After review, the Commission finds that the Settlement Agreement represents a reasonable and appropriate disposition of the matters asserted in the Administrative Complaint. The Commission therefore approves the Settlement Agreement.

2. **Mutual Agreement and Waiver of Rights.** Respondent has consented and agreed to the entry of this Consent Decree, and has agreed to be bound by the findings of fact, conclusions of law, and terms and conditions stated herein. Respondent has validly waived his rights to an administrative hearing before the Commission, to be represented by an attorney at such hearing, and to further notice and formal adjudication by the Commission of the charges arising from the Administrative Complaint. Respondent has also validly waived any and all rights to judicial review of this Consent Decree pursuant to Ala. Code § 34-24-367, the Alabama Administrative Procedure Act, Ala. Code §§ 41-22-1, *et seq.*, by extraordinary writ, or otherwise.

3. **Public Documents.** The Settlement Agreement and this Consent Decree shall constitute public records under the laws of the State of Alabama. The Settlement Agreement and this Consent Decree may be published or disclosed by the Board and/or the Commission without further notice to Respondent.

4. **Additional Violations.** Any violation of the requirements of this Consent Decree, or any new violation of state or federal laws or regulations, may result in the Board filing a petition to discipline Respondent's medical license. Nothing in this Consent Decree precludes the Board from bringing new administrative charges against Respondent based upon events and circumstances not raised in the Administrative Complaint.

5. **Retention of Jurisdiction.** The Commission retains jurisdiction for the purpose of entering such other and further orders and directives as may be required to implement the provisions of this Consent Decree.

6. **Judicial Notice.** Pursuant to Ala. Code § 41-22-13(4), Respondent is informed that the Board and/or the Commission may at any time take judicial notice of this Consent Decree, and/or any of the Findings of Fact herein, and may deem any of the findings or conclusions set forth in this Consent Decree to be conclusively established, all without further notice to Respondent.

Findings of Fact

1. Respondent has been licensed to practice medicine in the State of Alabama since March 3, 2009, having been issued license no. MD.29427. Respondent was so licensed at all relevant times.

2. On or about December 5, 2022, Respondent submitted or caused to be submitted an Alabama medical license renewal application for calendar year 2023. On that application, Respondent certified that the annual minimum continuing medical education requirement of 25 credits had been met or would be met by December 31, 2022. Respondent further represented that, if audited, he would have supporting documents.

3. Respondent did not earn any valid continuing medical education credits during 2022.

Conclusions of Law

1. The Commission has jurisdiction over the subject matter of the Administrative Complaint, and over the parties, pursuant to Ala. Code § 34-24-310, *et seq.*

2. The Commission finds, as a matter of law, that the determined facts constitute violations of Ala. Code § 34-24-360(23) and Ala. Admin. Code r. 545-X-5-.02.

Order/Discipline

Based upon the foregoing Findings of Fact and Conclusions of Law, it is ORDERED, ADJUDGED, AND DECREED:

1. That Respondent is assessed an administrative fine in the amount of two thousand five hundred dollars (\$2,500.00). In accordance with Ala. Admin. Code r. 545-X-3-.08(8)(d)(i), Respondent is ordered to pay the administrative fine within 30 days of this Order.¹

2. That Respondent is ORDERED to obtain 25 *additional* credits of AMA PRA Category 1™ or equivalent continuing medical education, in addition to the 25

¹ "The refusal or failure by a physician to comply with an order entered by the Medical Licensure Commission" may be a separate instance of "unprofessional conduct." See Ala. Admin. Code r. 545-X-4-.06(6).

credits already required for calendar year 2023, for a combined total of 50 credits, no later than December 31, 2023.

3. That no costs of this proceeding are assessed against Respondent at this time.

DONE on this the 1st day of August, 2023.

**THE MEDICAL LICENSURE
COMMISSION OF ALABAMA**

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:53:49 CDT

Craig H. Christopher, M.D.
its Chairman

EXHIBIT L

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

v.

**CHRISTOPHER PARKER GAY,
D.O.,**

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION OF
ALABAMA**

CASE NO. 2021-420

ORDER

This matter is before the Medical Licensure Commission of Alabama on the Bill of Costs filed on June 29, 2023 by the Alabama State Board of Medical Examiners. Respondent had 10 days in which to file written objections to the Bill of Costs. *See* Ala. Admin. Code r. 545-X-3-.08(10)(c). No such objections have been filed. Upon review, the Board's cost bill is approved, and the administrative costs of this proceeding are assessed against Respondent in the amount of \$1,592.48. *See* Ala. Admin. Code r. 545-X-3-.08(9), (10).

DONE on this the 1st day of August, 2023.

**THE MEDICAL LICENSURE
COMMISSION OF ALABAMA**

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:51:28 CDT

Craig H. Christopher, M.D.
its Chairman

EXHIBIT M

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

v.

AARON A.H. RAMIREZ, M.D.,

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION OF
ALABAMA**

CASE NO. 2023-033

ORDER

This matter is before the Medical Licensure Commission of Alabama on the “Joint Motion to Continue” filed on July 17, 2023. The Commission notes that Respondent, on April 10, 2023, filed a waiver of the 120-day limitation on the summary suspension of his license to practice medicine. Upon consideration, the Joint Motion to Continue is granted, and the hearing in this matter, previously scheduled for July 27, 2023, is hereby continued and reset for January 24, 2024, at 10:00 a.m.

DONE on this the 1st day of August, 2023.

**THE MEDICAL LICENSURE
COMMISSION OF ALABAMA**

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 11:48:32 CDT

Craig H. Christopher, M.D.
its Chairman

EXHIBIT N

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

BARRY GENE COLLINS, M.D.,

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION
OF ALABAMA**

CASE NO. 2023-208

ORDER SETTING HEARING
For Contested Cases Initiated by Administrative Complaint
Three-Member Panel Hearing

The Medical Licensure Commission has received the verified Administrative Complaint filed by the Alabama State Board of Medical Examiners in this matter. The Commission has determined that this matter is due to be set down for hearing under the provisions of Ala. Code § 34-24-361(e). This Order shall serve as the Notice of Hearing prescribed in Ala. Admin. Code r. 545-X-3-.03(3), (4). The Commission's legal authority and jurisdiction to hold the hearing in this matter are granted by Article 8, Chapter 24, Title 34 of the Code of Alabama (1975), and the particular sections of the statutes and rules involved are as set forth in the Administrative Complaint and in this Order.

1. **Service of the Administrative Complaint**

A copy of the Administrative Complaint and a copy of this Order shall be served forthwith upon the Respondent, by personally delivering the same to Respondent if he or she can be found within the State of Alabama, or, by overnight courier, signature required, to Respondent's last known address if he or she cannot be found within the State of Alabama. The Commission further directs that personal service of process shall be made by Randy Dixon, who is designated as the duly authorized agent of the Commission.

2. **Appointment of, and Referral To, Hearing Panel; Initial Hearing Date**

A hearing panel is hereby constituted, consisting of Commission members Christopher, Aldridge, and Nagrodzki, and this matter is hereby referred to such hearing panel for the conduct of a hearing and the entry of proposed findings to be considered by the full Commission. See Ala. Code § 34-24-366; Ala. Admin. Code r. 545-X-3-.14.

This matter is set for a hearing as prescribed in Ala. Code §§ 34-24-360, *et seq.*, and Ala. Admin. Code Chapter 545-X-3, to be held on Tuesday, September 12, 2023, at 10:00 a.m., at 3300 Cahaba Road, Suite 320, Birmingham, Alabama, 35223. Unless otherwise specified by the Commission, the hearing will be held in person. All parties and counsel are expected to appear and to be prepared for the hearing at this date, time, and place.

3. Appointment of Hearing Officer

The Commission appoints the Honorable William R. Gordon, Circuit Judge (Ret.) as the Hearing Officer in this matter, pursuant to Ala. Admin. Code r. 545-X-3-.08. The Hearing Officer shall exercise general superintendence over all pre-hearing proceedings in this matter, and shall serve as the presiding officer at the hearing, having and executing all powers described in Ala. Admin. Code r. 545-X-3-.08(1)(a)-(g).

4. Answer

Respondent shall file an Answer, as prescribed in Ala. Admin. Code r. 545-X-3-.03(6), within 20 calendar days of the service of the Administrative Complaint. If Respondent does not file such an Answer, the Hearing Officer shall enter a general denial on Respondent's behalf.

5. Rescheduling/Motions for Continuance

All parties and attorneys are expected to check their schedules immediately for conflicts. Continuances will be granted only upon written motion and only for good cause as determined by the Chairman (or, in his absence, the Vice-Chairman) of the Medical Licensure Commission. Continuances requested on grounds of engagement of legal counsel on the eve of the hearing will not be routinely granted.

6. Case Management Orders

The Hearing Officer is authorized, without further leave of the Commission, to enter such case management orders as he considers appropriate to the particular case. Among any other matters deemed appropriate by the Hearing Officer, the Hearing Officer may enter orders addressing the matters listed in Ala. Admin. Code r. 545-X-3-.03(5)(a)-(f) and/or 545-X-3-.08(1)(a)-(g). All parties will be expected to comply with such orders.

7. Manner of Filing and Serving Pleadings

All pleadings, motions, requests, and other papers in this matter may be filed and served by e-mail. All filings should be e-mailed to:

- The Hearing Officer, William Gordon (wrgordon@charter.net);
- The Director of Operations of the Medical Licensure Commission, Rebecca Robbins (rrobbins@almlc.gov);
- General Counsel of the Medical Licensure Commission, Aaron Dettling (adettling@almlc.gov);
- General Counsel for the Alabama Board of Medical Examiners, Wilson Hunter (whunter@albme.gov); and
- Respondent/Licensee or his or her counsel, as appropriate.

The Director of Operations of the Medical Licensure Commission shall be the custodian of the official record of the proceedings in this matter.

8. Discovery

Consistent with the administrative quasi-judicial nature of these proceedings, limited discovery is permitted, under the supervision of the Hearing Officer. *See* Ala. Code § 41-22-12(c); Ala. Admin. Code r. 545-X-3-.04. All parties and attorneys shall confer in good faith with one another regarding discovery. If disputes regarding discovery are not resolved informally, a motion may be filed with the Hearing Officer, who is authorized to hold such hearings as appropriate and to make appropriate rulings regarding such disputes.

9. Publicity and Confidentiality

Under Alabama law, the Administrative Complaint is a public document. The hearing itself is closed and confidential. The Commission's written decision, if any, will also be public. *See* Ala. Code § 34-24-361.1; Ala. Admin. Code r. 545-X-3-.03(10)(h), (11).

10. Stipulations

The parties are encouraged to submit written stipulations of matters as to which there is no basis for good-faith dispute. Stipulations can help to simplify and shorten the hearing, facilitate the Commission's decisional process, and reduce the overall costs of these proceedings. Written stipulations will be most useful to the Commission if they are submitted in writing approximately 10 days preceding the

hearing. The Hearing Officer is authorized to assist the parties with the development and drafting of written stipulations.

11. Judicial Notice

The parties are advised that the Commission may take judicial notice of its prior proceedings, findings of fact, conclusions of law, decisions, orders, and judgments, if any, relating to the Respondent. *See* Ala. Code § 41-22-13(4); Ala. Admin. Code r. 545-X-3-.09(4).

12. Settlement Discussions

The Commission encourages informal resolution of disputes, where possible and consistent with public interest. If a settlement occurs, the parties should notify the Hearing Officer, the Commission's Director of Operations, and Commission's General Counsel. The terms of settlement are subject to the approval of the Commission. If approved, the Commission will generally incorporate the settlement terms into a Consent Decree.

13. Subpoenas

The Commission has the statutory authority to compel the attendance of witnesses, and the production of books and records, by the issuance of subpoenas. *See* Ala. Code §§ 34-24-363; 41-22-12(c); Ala. Admin. Code r. 545-X-3-.05. The parties may request that the Hearing Officer issue subpoenas for witnesses and/or

documents, and the Hearing Officer is authorized to approve and issue such subpoenas on behalf of the Commission. Service of such subpoenas shall be the responsibility of the party requesting such subpoenas.

14. Hearing Exhibits

- A. Parties and attorneys should, if possible, stipulate as to the admissibility of documents prior to the hearing.
- B. The use of electronic technology, USB drives, CD's, DVD's, etc. is acceptable and encouraged for voluminous records. If the Commission members will need their laptop to view documents, please notify the Hearing Officer prior to your hearing.
- C. If providing hard copies, voluminous records need not be copied for everyone but, if portions of records are to be referred to, those portions should be copied for everyone.
- D. If a document is to be referred to in a hearing, copies should be available for each Commission member, the Hearing Officer, the Commission's General Counsel, opposing attorney, and the court reporter (12 copies).
- E. Index exhibits/documents for easy reference.
- F. Distribute exhibit/document packages at the beginning of the hearing to minimize distractions during the hearing.

15. Administrative Costs

The Commission is authorized, pursuant to Ala. Code § 34-24-381(b) and Ala. Admin. Code r. 545-X-3-.08(9) and (10), to assess administrative costs against the Respondent if he or she is found guilty of any of the grounds for discipline set forth in Ala. Code § 34-24-360. The Board of Medical Examiners [X]has / []has

not given written notice of its intent to seek imposition of administrative costs in this matter.

16. Appeals

Appeals from final decisions of the Medical Licensure Commission, where permitted, are governed by Ala. Code § 34-24-367.

DONE on this the 3rd day of August, 2023.

THE MEDICAL LICENSURE
COMMISSION OF ALABAMA

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-03 11:11:34 CDT

Craig H. Christopher, M.D.
its Chairman

Distribution:

- Honorable William R. Gordon (incl. Administrative Complaint)
- Rebecca Robbins
- Respondent/Respondent's Attorney
- E. Wilson Hunter
- Aaron L. Dettling

EXHIBIT O

**ALABAMA STATE BOARD OF
MEDICAL EXAMINERS,**

Complainant,

vs.

ERIC RAY BECK, M.D.,

Respondent.

**BEFORE THE MEDICAL
LICENSURE COMMISSION
OF ALABAMA**

CASE NO. 2022-099

ORDER SETTING HEARING
For Contested Cases Initiated by Administrative Complaint

The Medical Licensure Commission has received the verified Administrative Complaint filed by the Alabama State Board of Medical Examiners in this matter. The Commission has determined that this matter is due to be set down for hearing under the provisions of Ala. Code § 34-24-361(e). This Order shall serve as the Notice of Hearing prescribed in Ala. Admin. Code r. 545-X-3-.03(3), (4). The Commission's legal authority and jurisdiction to hold the hearing in this matter are granted by Article 8, Chapter 24, Title 34 of the Code of Alabama (1975), and the particular sections of the statutes and rules involved are as set forth in the Administrative Complaint and in this Order.

1. Service of the Administrative Complaint

A copy of the Administrative Complaint and a copy of this Order shall be served forthwith upon the Respondent, by personally delivering the same to Respondent if he or she can be found within the State of Alabama, or, by overnight courier, signature required, to Respondent's last known address if he or she cannot be found within the State of Alabama. The Commission further directs that personal service of process shall be made by _____, who is designated as the duly authorized agent of the Commission.

2. Initial Hearing Date

This matter is set for a hearing as prescribed in Ala. Code §§ 34-24-360, *et seq.*, and Ala. Admin. Code Chapter 545-X-3, to be held on Wednesday
December 20, 2023, at 10:00 a.m., at 848 Washington Avenue, Montgomery, Alabama, 36104. Unless otherwise specified by the Commission, the hearing will be held in person. All parties and counsel are expected to appear and to be prepared for the hearing at this date, time, and place.

3. Appointment of Hearing Officer

The Commission appoints the Honorable William R. Gordon, Circuit Judge (Ret.) as the Hearing Officer in this matter, pursuant to Ala. Admin. Code r. 545-X-3-.08. The Hearing Officer shall exercise general superintendence over all pre-hearing proceedings in this matter, and shall serve as the presiding officer at the

hearing, having and executing all powers described in Ala. Admin. Code r. 545-X-3-.08(1)(a)-(g).

4. Answer

Respondent shall file an Answer, as prescribed in Ala. Admin. Code r. 545-X-3-.03(6), within 20 calendar days of the service of the Administrative Complaint. If Respondent does not file such an Answer, the Hearing Officer shall enter a general denial on Respondent's behalf.

5. Rescheduling/Motions for Continuance

All parties and attorneys are expected to check their schedules immediately for conflicts. Continuances will be granted only upon written motion and only for good cause as determined by the Chairman of the Medical Licensure Commission. Continuances requested on grounds of engagement of legal counsel on the eve of the hearing will not be routinely granted.

6. Case Management Orders

The Hearing Officer is authorized, without further leave of the Commission, to enter such case management orders as he considers appropriate to the particular case. Among any other matters deemed appropriate by the Hearing Officer, the Hearing Officer may enter orders addressing the matters listed in Ala. Admin. Code

r. 545-X-3-.03(5)(a)-(f) and/or 545-X-3-.08(1)(a)-(g). All parties will be expected to comply with such orders.

7. Manner of Filing and Serving Pleadings

All pleadings, motions, requests, and other papers in this matter may be filed and served by e-mail. All filings should be e-mailed to:

- The Hearing Officer, William Gordon (wrgordon@charter.net);
- The Director of Operations of the Medical Licensure Commission, Rebecca Robbins (rrobbins@almlc.gov);
- General Counsel of the Medical Licensure Commission, Aaron Dettling (adettling@almlc.gov);
- General Counsel for the Alabama Board of Medical Examiners, Wilson Hunter (whunter@albme.gov); and
- Respondent/Licensee or his or her counsel, as appropriate.

The Director of Operations of the Medical Licensure Commission shall be the custodian of the official record of the proceedings in this matter.

8. Discovery

Consistent with the administrative quasi-judicial nature of these proceedings, limited discovery is permitted, under the supervision of the Hearing Officer. *See* Ala. Code § 41-22-12(c); Ala. Admin. Code r. 545-X-3-.04. All parties and attorneys

shall confer in good faith with one another regarding discovery. If disputes regarding discovery are not resolved informally, a motion may be filed with the Hearing Officer, who is authorized to hold such hearings as appropriate and to make appropriate rulings regarding such disputes.

9. Publicity and Confidentiality

Under Alabama law, the Administrative Complaint is a public document. The hearing itself is closed and confidential. The Commission's written decision, if any, will also be public. *See* Ala. Code § 34-24-361.1; Ala. Admin. Code r. 545-X-3-.03(10)(h), (11).

10. Stipulations

The parties are encouraged to submit written stipulations of matters as to which there is no basis for good-faith dispute. Stipulations can help to simplify and shorten the hearing, facilitate the Commission's decisional process, and reduce the overall costs of these proceedings. Written stipulations will be most useful to the Commission if they are submitted in writing approximately 10 days preceding the hearing. The Hearing Officer is authorized to assist the parties with the development and drafting of written stipulations.

11. Judicial Notice

The parties are advised that the Commission may take judicial notice of its prior proceedings, findings of fact, conclusions of law, decisions, orders, and judgments, if any, relating to the Respondent. *See* Ala. Code § 41-22-13(4); Ala. Admin. Code r. 545-X-3-.09(4).

12. Settlement Discussions

The Commission encourages informal resolution of disputes, where possible and consistent with public interest. If a settlement occurs, the parties should notify the Hearing Officer, the Commission's Director of Operations, and Commission's General Counsel. The terms of settlement are subject to the approval of the Commission. If approved, the Commission will generally incorporate the settlement terms into a Consent Decree.

13. Subpoenas

The Commission has the statutory authority to compel the attendance of witnesses, and the production of books and records, by the issuance of subpoenas. *See* Ala. Code §§ 34-24-363; 41-22-12(c); Ala. Admin. Code r. 545-X-3-.05. The parties may request that the Hearing Officer issue subpoenas for witnesses and/or documents, and the Hearing Officer is authorized to approve and issue such subpoenas on behalf of the Commission. Service of such subpoenas shall be the responsibility of the party requesting such subpoenas.

14. Hearing Exhibits

- A. Parties and attorneys should, if possible, stipulate as to the admissibility of documents prior to the hearing.
- B. The use of electronic technology, USB drives, CD's, DVD's, etc. is acceptable and encouraged for voluminous records. If the Commission members will need their laptop to view documents, please notify the Hearing Officer prior to your hearing.
- C. If providing hard copies, voluminous records need not be copied for everyone but, if portions of records are to be referred to, those portions should be copied for everyone.
- D. If a document is to be referred to in a hearing, copies should be available for each Commission member, the Hearing Officer, the Commission's General Counsel, opposing attorney, and the court reporter (12 copies).
- E. Index exhibits/documents for easy reference.
- F. Distribute exhibit/document packages at the beginning of the hearing to minimize distractions during the hearing.

15. Administrative Costs

The Commission is authorized, pursuant to Ala. Code § 34-24-381(b) and Ala. Admin. Code r. 545-X-3-.08(9) and (10), to assess administrative costs against the Respondent if he or she is found guilty of any of the grounds for discipline set forth in Ala. Code § 34-24-360. The Board of Medical Examiners [☒]has / [☐]has not given written notice of its intent to seek imposition of administrative costs in this matter.

16. Appeals

Appeals from final decisions of the Medical Licensure Commission, where permitted, are governed by Ala. Code § 34-24-367.

DONE on this the 1st day of August, 2023.

THE MEDICAL LICENSURE
COMMISSION OF ALABAMA

By:

E-SIGNED by Craig Christopher, M.D.
on 2023-08-01 14:48:06 CDT

Craig H. Christopher, M.D.
its Chairman

Distribution:

- Honorable William R. Gordon (incl. Administrative Complaint)
- Rebecca Robbins
- Respondent/Respondent's Attorney
- E. Wilson Hunter
- Aaron L. Dettling